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ABSTRACT OF DISSERTATION
THE DISORDERED REGULATION OF CALCINEURIN:  HOW CALMODULIN-
INDUCED REGULATORY DOMAIN STRUCTURAL CHANGES LEAD TO THE 
ACTIVATION OF CALCINEURIN
Calcineurin (CaN) is a highly regulated Ser/Thr protein phosphatase that plays 
critical roles in learning and memory, cardiac development and function, and 
immune system activation. Alterations in CaN regulation contribute to multiple 
disease states such as Down syndrome, cardiac hypertrophy, Alzheimer’s 
disease, and autoimmune disease.  In addition, CaN is the target of the 
immunosuppressant drugs FK506 and cyclosporin A.  Despite its importance, 
CaN regulation is not well understood on a molecular level. Full CaN activation 
requires binding of calcium-loaded calmodulin (CaM), however little is known 
about how CaM binding releases CaN’s autoinhibitory domain from the active 
site. Previous work has demonstrated that the regulatory domain of CaN (RD) is 
disordered. The binding of CaM to CaN results in RD folding. Folding of the RD in 
turn causes the autoinhibitory domain (AID) located C-terminal to the RD to be 
ejected from CaN’s active site. This binding-induced disorder-to-order transition 
is responsible for the activation of CaN by CaM.  In this work, we explore the 
nature of the disorder in the RD and its transition to an ordered state, 
demonstrating that the RD exists in a compact disordered state that undergoes 
further compaction upon CaM binding. We also demonstrate that a single CaM 
molecule is responsible for binding to and activating CaN. Finally, we determine 
that the CaM binding to CaN induces an amphipathic helix (the distal helix) C-
terminal to the CaM binding region. The distal helix undergoes a hairpin-like 
chain reversal in order to interact with the surface of CaM, resulting in the 
removal of the AID from CaN’s active site. We employ site-directed mutagenesis, 
size-exclusion chromatography, protein crystallography, circular dichroism 
spectroscopy, fluorescence anisotropy and correlation spectroscopy, and 
phosphatase activity assays to investigate the ordering of CaN’s regulatory 
domain, the stoichiometry of CaN:CaM binding, and the impact of the distal helix 
on CaM activation of CaN.
Keywords: Calcineurin, Calmodulin, Calcium Signalling, Intrinsically Disordered 
Protein, Folding Upon Binding
Victoria Beth Dunlap
6/21/2013
THE DISORDERED REGULATION OF CALCINEURIN:  HOW CALMODULIN-
INDUCED REGULATORY DOMAIN STRUCTURAL CHANGES LEAD TO THE 
ACTIVATION OF CALCINEURIN
By:
Victoria Beth Dunlap
Dr. Trevor P. Creamer
Director of Dissertation
Dr. Michael D. Mendenhall
Director of Graduate Studies
6/21/2013
ACKNOWLEDGEMENTS
There are so many people I need to thank, and words cannot express how each 
person’s contributions to my scientific life have led me to this point, but I will try 
anyway. I could not have had a better mentor than Trevor Creamer. He has been 
incredibly patient and supportive through both my scientific missteps and 
successes, even if he can be maddeningly optimistic. I have also had great lab 
mates along the way: Julie Rumi-Masante, Terrence Lester, and Erik Cook. Julie 
was fantastically helpful, and chatting with her always shed light on my scientific 
dilemmas. Julie also enabled my coffee habit with daily Starbucks runs. Anybody 
who knows Terrence knows that he is... entertaining, and never short on energy. 
He is always  fun to be around, and could provide a good distraction when the 
science was too much. Erik has been great for interesting conversations.
The friends that I have made in graduate school have kept me sane through this 
crazy experience. Kristen Kelps, Katie Mattinson, and Erin Miller have always 
been there when I needed shopping, food, commiseration, and plenty of laughter. 
It always brightens my day when Kara Larson, Stacy Webb, or Caitlyn Riedmann 
stop by my desk to chat. Kara is a great listener when I need to talk through 
science problems.  Thank you Clint Smith, Andres Chang, Jeanette Chang, and 
Alvaro Vindell for the wonderful meals and conversations that we have shared 
through the years.
iii
I would like to thank the members of my committee: Dr. David Rodgers, Dr. Matt 
Gentry, and Dr. James Geddes. They have always offered helpful comments, 
criticisms, and insights that have furthered the work I was able to do. Their doors 
have always been open to me when I have needed help. Thanks, also, to Dr. 
Jason DeRouchey, my outside examiner, for taking the time to read my 
dissertation and evaluate my scientific progress. I would also like to thank Dr. 
DeRouchey and his graduate student, Xialou Zhang, for their help in doing 
fluorescence correlation spectroscopy experiments. Emily Holbrook, an REU 
student for Dr. Creamer, began the crystallography work that I did for my 
dissertation, and for that I thank her. Thanks to  Dr. Craig Vander Kooi and Hou-
fu Guo teaching me what goes into solving crystal structures and for helping me 
with the refinement when I kept destroying our structure. I would like to thank the 
current and former director of graduate studies, Dr. Kevin Sarge and Dr. Mike 
Mendenhall. Dr. Sarge was very helpful in my transition from IBS to the 
Biochemistry department, and Dr. Mendenhall has made sure that I have had all 
of my paperwork in order to ensure that I can graduate. The Biochemistry 
department has been a great place to work thanks to all of the present and 
former faculty, staff, and students. 
I want to thank my family. My parents, Michael and Mary Jo O’Bannon, have 
always, always been there for me. They have shaped me, supported me, and 
cared for me my entire life. I would not be the person I am today without their 
guidance. I love them very much and owe them everything. My brother, Barrie 
iv
O’Bannon, has always been my co-conspirator. He and I played together, fought 
together, and grew up together. He is always someone I can lean on. 
Finally, I thank my husband, Joe Dunlap, for being my anchor. He is calm and 
compassionate when I am upset and a great problem solver when I need a 
resolution. He can always make me laugh and lift my spirits. I love him more than 
words can say, and I would not be here today if it were not for him.
v
Table of Contents
Acknowledgements.............................................................................................iii
.......................................................................................................List of Tables! ix
.....................................................................................................List of Figures! x
............................................................Chapter 1: Background and Introduction! 1
..............................................................................................Calcineurin: an overview 1
....................................................................................................Calcineurin Signaling 2
................................................................Nuclear factor of activated T-cells (NFAT) 2
.........................................................Long-Term Depression at Excitatory Synapses 4
...............................................................................CaN Signaling in Human Health 5
...............................................................................Calcineurin Structure and Activity 7
.............................................................................................................Calcineurin A 7
.............................................................................................................Calcineurin B 8
..................................................................................................Calcineurin Activation 9
Exploration of the Regulatory Domain and Regulatory Domain/CaM interactions: 
..................................................................................................Dissertation Overview 11
.....................................................................Chapter 2: Materials and Methods! 20
.......................................................................................................................Materials 20
...........................................................................................Plasmid expression vectors 20
..................................................................................................................Mutagenesis 20
................Expression and purification of recombinant CaN and CaN mutant proteins 21
...................Expression and purification of recombinant RD and RD mutant proteins 22
..............Expression and purification of recombinant CaM and CaM mutant proteins 24
.........................................................................................................................Peptides 25
........................................................................................................Circular Dichroism 26
vi
...................................................................................................Fluorescence Labeling 26
...........................................................................................Fluorescence Spectroscopy 27
....................................................................................Size-exclusion chromatography 27
.................................................................................................Structure determination 28
....................................................................................Calcineurin phosphatase assays 29
.............................................Table 2.1: PCR cycles for generation of the RDc mutant 34
.....................................................Table 2.2: Data collection and refinement statistics 35
.................Chapter 3: Disorder to order in the regulatory domain of calcineurin! 36
...................................................................................................................Introduction 36
...........................................................................................................................Results 38
The RD of CaN is devoid of persistent secondary structure, but gains α-helix upon 
..............................................................................................................CaM binding 38
...............................................................................................pCaN:CaM anisotropy 39
...................................................................................................RD:CaM anisotropy 40
........................................................................Translational diffusion of RD ± CaM 41
.....................................................................................................................Discussion 42
Chapter 4: Stoichiometry of the calcineurin regulatory domain-calmodulin 
..............................................................................................................complex! 51
...................................................................................................................Introduction 51
...........................................................................................................................Results 54
................................................................................Size-Exclusion Chromatography 54
.............................................................Crystal structure of the CaM:pCaN complex 56
.....................................................................................................................Discussion 57
Chapter 5: The distal helix in the regulatory domain of calcineurin is important for 
.........................calcineurin-regulatory domain stability and calcineurin function! 71
...................................................................................................................Introduction 71
vii
...........................................................................................................................Results 74
.................RD:CaM secondary structure is similar to that of the RD-AID-CT:CaM 74
.......................................CaM induced RD structure is less stable than pCaN:CaM 74
Disruption of the hydrophobic face of the putative distal helix alters CaM induced 
....................................................................................................secondary structure 75
Disruption of the hydrophobic face of the putative distal helix alters CaM induced 
..............................................................................................................helix stability 75
Disruption of the hydrophobic face of the putative distal helix diminishes CaM 
................................................................................................activated CaN activity 76
.....................................................................................................................Discussion 76
Chapter 6: Conclusions and future directions, a model for calcium/CaM 
...............................................................................................regulation of CaN! 86
.........................................................................................................References! 99
..................................................................................................................VITA ! 117
viii
List of Tables
................................................Table 2.1: PCR cycles for generation of the RDc mutant 34
........................................................Table 2.2: Data collection and refinement statistics 35
Table 3.1: Anisotropies and diffusion coefficients of pCaN, CaM, RD, and complexes 50
Table 4.1: Size exclusion chromatography standards run on the Superdex 75 10/300 GL 
............................................................................................................column 70
Table 5.1: Kinetic parameters of CaN and CaN distal helix mutants for dephosphorylation 
..............................................................................................of p-RII peptide 85
ix
List of Figures
..........................................................Figure 1.1 NFAT domains and phosphorylations 13
.............................................................Figure 1.2 Schematic of NFAT docked to CaN 14
.......................................................................Figure 1.3 Calcineurin domain structure 15
......................................................Figure 1.4 Activation of calcineurin by calmodulin 16
...............................................................................................Figure 1.5 CaM structure 17
........................Figure 1.6 Structure of CaM with CaMBR of CaN, 2:2 stoichiometry 18
Figure 1.7 Schematic of CaN domains and CaM binding region placement within the 
........................................................................................regulatory domain 19
......................................................................Figure 2.1 Sequence of the RD construct 30
.................................Figure 2.2 Sequence of the RD portion of CaN and RD mutants 31
....................................................................Figure 2.3 Sequence of the RDc construct 32
...................Figure 2.4 Schematic of primer design to create the RDc deletion mutant 33
.........................................Figure 3.1: Calcineurin domain structure and RD construct 46
.......................................................................Figure 3.2: RD, CaM, pCaN CD spectra 47
...........................................................................Figure 3.3: Fluorescence anisotropies 48
.......................................Figure 4.1: Calcineurin domain structure and RDc construct 63
.....................................................Figure 4.2: CaM and CaM:target peptide structures 64
................................................Figure 4.3: CaM, RDc size-exclusion chromatography 65
...........................................................Figure 4.4: FLMMc binding pocket interactions 66
..........................................................Figure 4.5: FLMMn binding pocket interactions 67
.......................................Figure 4.6: pCaN R408 salt bridges with CaM D80 and E83 68
......................................................Figure 4.7: pCaN F410 and CaM P43 ring stacking 69
Figure 5.1: Domain ordering of CaM activated kinases compared to the domain ordering 
.........................................................................................................of CaN 81
x
..............Figure 5.2: Calcineurin domain structure and regulatory domain schematics 82
........................Figure 5.3: CD spectra and melts of RD, CaM, pCaN, and complexes 83
.....Figure 5.4: CD spectra and melts of RD mutants and RD mutant:CaM complexes 84
....................................................................Figure 6.1: Sequence alignment of the RD 97
.....................................Figure 6.2: Model for the activation of CaN by calcium/CaM  98
xi
Chapter 1: Background and Introduction
Calcineurin: an overview
Calcineurin (CaN) is a heterodimeric calcium/calmodulin activated serine/threonine 
protein phosphatase. It was originally  identified by three separate groups: Wang and 
Desai,1 Watterson and Vanaman,2 and Klee and Krinks.3 Each group  identified CaN as an 
inhibitor of the calmodulin (CaM) activated cyclic 3’, 5’-nucleotide phosphodiesterase. 
The reason for CaN’s apparent inhibition of the cyclic 3’, 5’-nucleotide 
phosphodiesterase is that CaN binds to and thereby depletes CaM,  preventing activation 
of cyclic 3’, 5’-nucleotide phosphodiesterase by CaM.
It was later learned that  CaN is a calmodulin activated protein phosphatase and has a 
multitude of targets and interacting proteins. CaN is well conserved among eukaryotes. In 
lower eukaryotes, such as S. cerevisiae, CaN functions in pathways for growth, motility, 
stress response, and calcium homeostasis, among others.4 In humans CaN has many 
targets across most tissue types, but CaN’s most well-known target is the nuclear factor of 
activated T-cells (NFAT) family of transcription factors. It is CaN’s activation of NFATs 
that makes CaN the target of the immunosuppressant  drugs that are given to patients who 
have had organ or tissue transplants to avoid rejection of the transplant.4,5
Besides immune system involvement, CaN plays a role in cardiac, vasculature, nervous 
system, and musculature development. CaN signaling is also necessary for learning and 
memory, skeletal muscle growth, and immune system activation.4 Because of its roles in 
these varied signaling systems inappropriate CaN regulation has been implicated in a 
number of pathological states including Alzheimer’s disease,6 Down syndrome,7 and 
cardiac hypertrophy.8,9 
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Calcineurin Signaling
Nuclear factor of activated T-cells (NFAT)
The nuclear factor of activated T-cells (NFAT) family of transcription factors is composed 
of five members, NFAT1-5 (or NFATc1-c5), and CaN regulates NFATs 1-4.10 The NFATs 
are transcription factors that can activate a variety of gene programs depending on the 
tissue type, NFAT type, number and location of NFAT phosphorylations, and binding 
partner that the NFAT associates with when in the nucleus.11-13 Under resting cell 
conditions NFAT is maintained inactive in the cytosol by multiple phosphorylations that 
prevent use of the NFAT nuclear localization signal (NLS).14,15 The number and location 
of the phosphorylations also determine NFAT’s affinity  for DNA, but the mechanism by 
which phosphorylations determine DNA affinity and hide the NLS are unknown.14-18
The NFATs interact with CaN via a conserved ~300 amino acid sequence that is encoded 
by a single exon.11,19 This CaN interacting domain begins ~100 residues from the N-
terminus and is N-terminal to the DNA binding region (Figure 1.1). The CaN interacting 
domain includes two serine rich gatekeeper regions (SRRs) and three SPxx motifs, all of 
which can have multiple phosphorylations. Additionally, this region contains two CaN 
interacting motifs: a PxIxIT motif and a LxVP motif.11 The PxIxIT forms a β-strand that 
lines up with and completes a β-sheet on the outer edge of CaN’s catalytic domain.20 The 
LxVP motif interacts with CaN at the interface of the two CaN subunits.21 These two 
docking sites are on the same face of CaN as the active site but opposite sides of the 
catalytic domain. NFAT’s phosphorylations are in the region between these two motifs, 
thus the CaN binding motifs act as anchors to bring the phosphorylation sites in 
proximity to CaN’s active site (Figure 1.2). Many other CaN targets employ one or both 
of these binding motifs to dock with CaN. The affinity of substrates for CaN seems to be 
determined by the variable amino acids in the PxIxIT or LxVP motif that the substrate 
uses.22  It is thought  that these docking sites are what determine CaN’s substrate 
specificity.21
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When intracellular calcium levels rise, CaN is activated by  calcium/calmodulin and can 
then dephosphorylate NFAT. CaN dephosphorylation of sites in NFAT’s CaN interacting 
domain exposes the NFAT NLS which is located in the same domain. Once NFAT’s NLS 
is revealed it  is relocated from the cytoplasm to the nucleus.14-18 In the nucleus NFATs 
can bind DNA in monomer form, as a homodimer, or as a heterodimer with a number of 
different transcription factor partners: AP-1 (Fos-Jun heterodimer), GATA4, and MEF2 to 
name a few.5,23-25 The dimer partner helps to determine which genes are affected by 
NFAT and allows for integration of multiple signaling pathways.
Once in the nucleus and partnered with the appropriate partner, NFAT acts as a 
transcription factor or repressor to up-regulate or down-regulate entire gene programs. 
NFAT acts on distal promotors, and its consensus sequence is (A/T)GGAAA.5 When 
NFAT is paired with other transcription factors, the dimer binds to composite sites with 
both the NFAT consensus sequence and the sequence for the NFAT partner.11 The various 
NFATs often have overlapping functions, and deletion of two or more NFAT types are 
usually necessary to observe an altered phenotype.26
Calcineurin/NFAT signaling is necessary for proper fetal development and adult 
homeostasis in many calcium sensitive tissues including the heart, vasculature, nervous 
system, immune system, skeletal muscles, bone, pancreatic β-cells, and kidneys.13 During 
fetal heart development, CaN dephosphorylation of NFAT3 and NFAT4 leads to an 
increase in cardiac contractile proteins and oxidative metabolic proteins; signaling 
through NFAT1 is necessary for valve development; and signaling through NFAT2 is 
involved in angiogenic remodeling.9,24,27 CaN/NFAT signaling was discovered via its role 
in the immune system and is very well studied in this system.28,29 NFATs are necessary 
for differentiation of T-cells, and NFAT1 and NFAT2 are required for cytokine production 
in stimulated T-cells.30 In skeletal muscles, CaN/NFAT signaling, under conditions of 
chronic muscle activity, induces expression of myosin heavy chain 1 (MyHC1). MyHC1 
expression is necessary for muscle fiber switching from fast-twitch to slow-twitch fibers.
11 NFAT2 activity is essential for osteoclast  progenitor differentiation in bones.31,32 In 
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pancreatic β-cells the insulin gene has a known NFAT promotor, and β-cell specific 
depletion of CaN in mice results in age-dependent diabetes.33-35 CaN signaling through 
NFAT is necessary for renal development at the earliest stages and plays a role in salt and 
water homeostasis.36-38 
The above examples are just a fraction of the signaling pathways under the influence of 
CaN/NFAT signaling. Additionally, CaN has a multitude of targets besides NFAT in these 
and other systems. In the following section I will discuss CaN’s well known, if not fully 
understood, role in long-term depression at excitatory synapses. This example is given in 
order to explore important non-NFAT CaN signaling.
Long-Term Depression at Excitatory Synapses
Long-term potentiation (LTP) and long-term depression (LTD) are mechanisms used at 
the post-synaptic neurons of excitatory synapses to sensitize or desensitize, respectively, 
the receiving neuron to excitation stimuli. LTP strengthens the connection between 
neurons while LTD weakens it. These processes are important in learning and memory. 
LTP and LTD are very  complex and the mechanisms for LTP and LTD induction can be 
different depending on the type and architecture of the synapse. What follows is a brief 
overview of the role CaN plays in LTD.39 
The NMDA receptor (NMDAR), calcium-permeable AMPA receptor (AMPAR), and 
calmodulin activated kinase II (CaMKII) are important in LTP.39-43 NMDAR and AMPAR 
are both glutamate receptor cation channels located on post-synaptic neurons. NMDAR is 
also a voltage-gated channel. When glutamate binds the receptors AMPARs are opened, 
allowing the influx of cations, including calcium. In addition to glutamate binding, 
NMDAR requires depolarization of the post-synaptic neuron to open. Depolarization 
releases a magnesium ion in NMDAR pores, allowing the influx of cations.39-41 LTP can 
occur if the excitatory stimuli is strong enough causing both receptors to open, and the 
influx of calcium through NMDARs allows the activation of CaMKII. CaMKII then 
phosphorylates AMPARs, making them more sensitive to excitatory  stimuli, thereby 
4
reinforcing the stimulus. CaMKII also assists in increasing the number of AMPARs at the 
membrane.39,41,42
LTD occurs when a persistent, weak excitatory  stimulus is applied to the post-synaptic 
neuron. This opens AMPARs, allowing a cation influx that is not strong enough to 
depolarize the cell. Lack of depolarization maintains NMDARs in their closed state so 
that CaMKII is inactive.39 CaN is anchored to the dendritic membrane by  the scaffolding 
protein AKAP79.12 When AMPARs allow the influx of calcium, CaN is activated and 
dephosphorylates AMPARs, desensitizing them to excitatory stimuli.12,43 CaN activity 
may supersede CaMKII activity  under these circumstances because, while both are 
calcium/calmodulin activated, CaN has a much higher affinity  for CaM than CaMKII 
does (KD ~1pM and ~300nM, respectively) and because CaMKII is associated with 
NMDARs when inactive, not AMPARs .44,45 While, as mentioned, LTP and LTD are 
much more complex than the brief explanation given, CaN’s role in LTD is its 
dephosphorylation of AMPARs, and this dephosphorylation is crucial for LTD. 
CaN Signaling in Human Health
We have discussed CaN’s role in the development and maintenance of several human 
organ/tissue systems, so we can see how altered CaN signaling can lead to a host of 
different pathological states. CaN mis-regulation has been implicated in cardiac 
hypertrophy,8,9 Alzheimer’s disease,6  and Down syndrome.7 
When CaN/NFAT signaling is chronically activated in adults, the fetal gene program is 
reactivated, and it leads to cardiac hypertrophy  which is a leading predictor of congestive 
heart failure. In fact, constitutively activated CaN, NFAT3, or NFAT4 can induce massive 
cardiac hypertrophy in mice, including increased myocyte size, an increase in collagen 
and fibrous tissue, and often congestive heart failure or sudden death.9,24,27
CaN has been shown to dephosphorylate Tau protein. The hyperphosphorylated form of 
Tau can form neurofibrillary tangles, a hallmark of Alzheimer’s disease in human brain. 
CaN activity is shown to be decreased in the brains of Alzheimer’s disease patients. 
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Decreased CaN activity could lead to hyperphosphorylated Tau, and, thereby, 
neurofibrillary tangles.6,46
Regulator of calcineurin 1 (RCAN1) is an endogenous regulator of CaN.47 The gene for 
RCAN1 is found in the Down syndrome critical region (DSCR) of chromosome 21, and 
is overexpressed in individuals with Down syndrome. 48 Overexpressed RCAN1 
chronically inhibits CaN. Mental retardation, muscle hypotonia, and immune deficiency 
are all characteristic Down syndrome pathologies.49 It is thought that chronic CaN 
inhibition by RCAN1 contributes to these pathologies.7,48 As mentioned in the previous 
CaN signaling sections, CaN contributes to learning and memory, skeletal muscle 
development and maintenance, and immune system activation. Additionally, Down 
syndrome patients almost invariably develop early-onset Alzheimer’s disease if the 
patient lives past ~35 years.7,49 It is possible that decreased CaN activity due to increased 
RCAN1 levels contributes to this occurrence of Alzheimer’s disease.
Finally, CaN is the target of the immunosuppressant drugs FK506 (also known as 
tacrolimus) and cyclosporin A.18,50 These drugs are necessary  for patients who have had 
tissue or organ transplants as they help to prevent rejection of the transplant. In cells, 
FK506 binds FKBP12 (FK506 binding protein 12), and cyclosporin A binds cyclophilin. 
These proteins are prolyl-isomerases. The binding of the drugs to their protein partners 
allows the complex to then bind CaN, preventing NFAT binding and dephosphorylation.
51-54 Without NFAT signaling, T-cells are not activated, which allays immune system 
attack on transplanted tissues.
The vast network of CaN/NFAT signaling, CaN signaling in the very important process of 
LTD, and the impact of altered CaN signaling on human health demonstrates the large 
scope and importance of CaN function. However, despite extensive studies concerning 
CaN there is much we do not understand about the protein itself and its activation by 
calcium-loaded calmodulin (CaM). In the following sections, we will explore what is 
known about CaN structure and activation as well as some of the aspects of CaN 
structure and activation that we do not fully understand.
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Calcineurin Structure and Activity
CaN is a heterodimer composed of a 57-61kDa A chain (CnA) and a 19kDa B chain 
(CnB). CnA is composed of the catalytic domain, CnB binding helix (CnBBH), 
regulatory domain (RD), autoinhibitory domain (AID), and C-terminal tail (CT) (Figure 
1.3).55  At low calcium concentrations the AID resides in the catalytic site of CnA, 
keeping the enzyme inactive. When calcium levels rise, calcium loaded CaM  binds to the 
CaM binding region (CaMBR) located in the regulatory domain of CnA. CaM binding 
releases the AID from the catalytic site, activating CaN (Figure 1.4).56 CnB is a calcium 
binding EF hand protein that is structurally  homologous to CaM. While CnB can bind up 
to four calcium ions, it is constitutively bound to CnA, regardless of calcium 
concentrations.57 There are three CaN isoforms: αCaN is found primarily in neurons, 
βCaN is ubiquitous, and γCaN is testes specific. The differences in regulation and activity 
between isoforms is unclear.58 In this work CaN refers to αCaN.
Calcineurin A
The catalytic domain of CnA has a β-sandwich fold consisting of two central β-sheets 
surrounded by a mixture of α-helices and β-sheets (Figure 1.3).51,52 This architecture is 
consistent with the phosphoesterase motif common in enzymes involved in hydrolyzing 
phosphoester bonds including protein phosphatase 1, protein phosphatase 2a, alkaline 
phosphatase, and phosphodiesterase.59 The active site of CaN has a dinuclear metal center 
consisting of Fe3+-Zn2+. The Fe3+ is coordinated by Asp90, His92, Asp118, and three 
waters. The Zn2+ is coordinated by Asn150, His199, His 281, Asp118, and a water that it 
shares with the Fe3+.4,52 In addition, it is thought that Arg122 and Arg254 are necessary  to 
help  stabilize the negative charge from phosphate in the active site during catalysis.4,52 It 
is believed that the catalysis proceeds via direct transfer of the phosphate moiety to a 
metal activated water molecule. The metal activated water initiates a nucleophilic attack 
on the phosphate group, assisted by the two histidines.4 
Beyond the catalytic domain, which is the N-terminal portion of CnA, there is the 
CnBBH where CnB binds. C-terminal to the CnBBH is the regulatory  domain (RD). The 
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RD is a disordered stretch of CnA which houses the CaMBR and will be discussed in 
more detail below. At the end of the RD is the AID which exists as a distorted helix in the 
catalytic site in the CaN crystal structure.52 Beyond the AID is the C-terminal tail (CT) 
which is disordered and has no known function (Figure 1.3).
Calcineurin B
CnB is a calcium binding EF hand protein that is homologous to CaM. It has an N-
terminal lobe and a C-terminal lobe, each of which binds two calcium ions.57 The C-
terminal lobe binds calcium with high affinity  and is considered to be constitutively 
calcium and calcineurin bound. The N-terminal lobe has a lower calcium affinity  and 
must bind calcium for CaN to have efficient phosphatase activity  against peptide 
substrates.56,60 CnB binds the CnBBH of CnA in an antiparallel fashion. The C-terminal 
lobe binds to the N-terminal portion of the CnBBH and is adjacent to the CnA catalytic 
domain while the N-terminal lobe binds to the C-terminal portion of the CnBBH.
Studies suggest that CnB plays a regulatory role in CaN function. Without calcium (in the 
presence of EGTA) limited proteolysis with chymotrypsin cleaves the CnB linker and 
first helix, but the CaMBR containing RD, is protected. Conversely, in the presence of 
calcium, all of CnB is protected and the RD is rapidly  degraded.56 This suggests that a 
portion of the RD interacts with the CnBBH when the N-terminal lobe of CnB is not 
calcium bound, but  a conformational change occurs upon calcium binding that releases 
the RD, likely so that it is available for interaction with CaM. 
CnB also appears to impact substrate LxVP motif interaction with CaN’s LxVP docking 
site which is critical for substrate dephosphorylation and thought to be a mode of 
substrate recognition.21,61-63 The LxVP docking site is found at the CnA-CnB interface.21 
Substrate only binds the LxVP site of active CaN.61-63 A truncated CnA (catalytic domain 
and CnBBH only) with CnB bound shows normal Vmax levels with a peptide substrate, as 
would be expected without the AID in the active site. However, the Km of this truncated 
CaN is five times higher than active, native CaN. Addition of calcium (binding the N-
terminal lobe of CnB) reduces the Km to native levels.64 This suggests that CnB calcium 
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binding affects CaN substrate affinity, giving CnB a regulatory, not just structural, role in 
the CaN heterodimer.
Calcineurin Activation
Under resting calcium conditions, CaN is maintained in an inactive state by its 
autoinhibitory domain (AID) bound to CaN’s catalytic site. When calcium levels rise, 
calmodulin (CaM) binds calcium and then binds to the calmodulin binding region 
(CaMBR) of CaN, located in the regulatory domain (RD) (Figure 1.4).56 
CaM is a 148 amino acid, 16.7kDa protein that is a major transducer of calcium signaling 
in cells.65 CaM binds to and regulates ~300 cellular targets.66 CaM is composed of two 
lobes connected by a flexible linker, often referred to as a dumbbell shape (Figure 1.5a). 
CaM has four calcium binding sites, two in each lobe. While there are several types of 
sequences that CaM  binds to, calcium loaded CaM preferentially  binds to basic, 
amphipathic, α-helical sequences (BAA sequences).44,66,67 The CaMBR of CaN is a BAA 
sequence.66,68 In some cases, as with CaN, the CaM target sequence is disordered but 
prone to α-helicity, as measured by the ability  of 2,2,2-Trifluorethanol (TFE) to induce 
helix in the sequence.69 TFE is well known to induce α-helical structure in peptides 
possessing a propensity to be helical.
Typically, when CaM binds BAA sequences, the CaM central linker helix becomes 
flexible and its two CaM  lobes wrap around the target to form a compact ellipsoid 
(Figure 1.5b).66,67 The manner in which CaM binds CaN is still not completely 
understood. Crystal structures of CaM bound to a peptide of the CaMBR of CaN done by 
Ye et. al. and Majava et. al show CaM  bound to CaN in a 2:2 manner with one lobe of 
CaM bound to one end of a CaMBR peptide while the other lobe is bound to another 
CaMBR (Figure 1.6). However, small angle x-ray scatter (SAXS) and size exclusion 
chromatography  (SEC) performed by Majava et al. demonstrated a 1:1 CaM:CaMBR 
complex.70 Native-gel analysis and SEC on CaM:CaMBR by Ye et al. showed both a 2:2 
complex and a 1:1 complex, with 1:1 being the dominate species. Also, through extensive 
hydrodynamic studies, O’Donnell et al. demonstrate a 1:1 CaM:CaMBR complex that 
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likely exhibits the canonical wrap-around CaM binding.44 This leaves some uncertainty 
about the physiological stoichiometry of CaM binding to CaN, at important aspect of 
CaM regulation of CaN for us to understand.
CaN’s CaMBR is located in the regulatory domain (RD) of CaN. The CaMBR begins 20 
residues from the end of the CnBBH and ends 52 residues from the beginning of the AID. 
Trypsin digests and other hydrolysis experiments by Manalan and Klee, and Yang and 
Klee, respectively, demonstrated that the RD is readily hydrolyzed, showing that it  is 
flexible and accessible in nature.58,71 In the crystal structure of full length CaN the 
electron density for the RD and C-terminal tail (CT) are missing suggesting that these 
regions are highly mobile.52 Additionally, Romero and Dunker noted that the sequence of 
the RD, enriched in charged and polar residues, gives it the potential to be disordered.72 
Work by Rumi-Masante et al. showed by H/D exchange mass spectrometry and circular 
dichroism spectroscopy  that a fragment corresponding to CaN’s RD, AID, and CT (RD-
AID-CT) is disordered in the absence of CaM, though the AID is well-ordered in full-
length, inactive CaN.73 The RD portion of this fragment contains the CaM  binding region 
and the 52 residues that separate it from the AID (Figure 1.7). Canonically, CaM’s two 
lobes wrap around its target site and induce α-helix in that sequence. Knowing now that 
the overall RD is disordered, this leaves 52 residues of disorder between the end of the 
CaMBR and the beginning of the AID, suggesting that CaM  binding would not be able to 
forcibly remove the AID from the active site. How then does CaM activate CaN with its 
CaMBR and AID 52 residues apart and with those 52 residues being disordered?
The trypsin digests performed by Manalan and Klee, aside from demonstrating that the 
RD is flexible and accessible to proteases, also suggested that the RD of CaN undergoes a 
large conformational change upon CaM binding as the highly unprotected RD becomes 
protected from trypsin digest when CaN is preincubated with CaM.71 Rumi-Masante et al. 
also showed that upon CaM binding, ~50 residues within the RD become protected from 
H/D exchange and that the RD gains approximately fifty  residues of α-helicity.73 About 
half of these residues reside in the CaMBR while the remainder are C-terminal to the 
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CaMBR, between it  and the AID. The high protection and α-helicity  of the CaMBR when 
CaM is bound is expected given the very tight  binding between CaM and CaN (KD 
~1pM) and the manner in which CaM  typically binds its targets.44 The protection and 
helicity in the region between the CaMBR and AID, suggested by RD protection in 
Manalan and Klee’s CaN/CaM trypsin digests and confirmed by Rumi-Masante et al., 
suggests a larger scale structuring than just the sequence CaM directly binds.71,73
Exploration of the Regulatory Domain and Regulatory Domain/CaM interactions: 
Dissertation Overview
CaN signaling has been demonstrated to be important in many signaling pathways and 
tissues. Its interactions have been well studied, especially given its importance as the 
target for immunosuppressant drugs. However, there is still much we do not understand 
about the CaN protein itself, specifically concerning CaN’s regulatory  domain (RD) 
interaction with CaM. Through work from multiple groups, we know that the RD is 
disordered in the absence of CaM  but undergoes an ordering conformational change upon 
CaM binding.52,58,71-73 Beyond this, there is much we do not understand about  the 
interaction. 
What is the shape of the RD alone? To term a protein or a protein region “disordered” 
only tells us that the protein does not adopt a well-ordered tertiary  structure. Within this 
definition, the protein can exist anywhere from an ensemble of completely disordered 
string-like shapes to a molten-globule shape that  has secondary  structure, but where the 
tertiary  structure is ill-defined. We know from the work done by  Rumi-Masante, et al. 
that the RD is not on the molten-globule end of the disorder spectrum as CD spectra of 
the RD -AID-CT indicate it has no persistent secondary structure.73 However, the 
question remains, is the RD more compact in shape or extended? Chapter three of this 
work explores the shape of the RD in the absence of CaM  in order to help characterize its 
disordered state. Chapter three also investigates the overall shape of the CaM:RD 
complex. Fluorescence anisotropy, fluorescence correlation spectroscopy (FCS), and 
circular dichroism (CD) spectroscopy are all employed in this endeavor.
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Chapter four delves into the stoichiometry of the CaM:RD complex. As noted, the 
stoichiometry of this complex seems to exist at 2:2 in crystal structures; at both 2:2 and 
1:1 in solution work, with 1:1 being the dominant species; and at 1:1 in hydrodynamic 
studies.44,70,74,75 In an attempt to reconcile these views I employ crystallography to 
investigate the structure of CaM  bound to a peptide of CaN’s CaMBR (pCaN), and size 
exclusion chromatography (SEC) is used to explore the CaM:RD stoichiometry. RD is 
used in the SEC to determine if using a larger portion of CaN than just the CaMBR 
would impact the stoichiometry of CaM binding.
Rumi-Masante, et al. demonstrated that the RD-AID-CT undergoes an ordering upon 
CaM binding that extends beyond the CaMBR.73 There are ~50 residues that gain 
structure upon CaM  binding while the CaMBR is 24 residues in length. The remaining 
order is gained in the region between the end of the CaMBR and the beginning of the 
AID and is α-helical.73 Chapter five of this work investigates the nature of this ordering 
and its impact on CaN activity using site-directed mutagenesis, CD spectroscopy, CD 
thermal melts, and CaN phosphatase activity assays. 
Chapter six serves as summation and further interpretation of the data presented in 
previous chapters. Future experiments are also suggested to expand upon this work and to 
further clarify the CaM:RD interaction both on its own and in the full context of 
calcineurin.
Copyright © Victoria Beth Dunlap
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Figure 1.1 NFAT domains and phosphorylations
Schematic of NFAT domains is shown. Red circles are phosphorylation sites. Sequence of 
CK1 docking site and CN docking site shown above. CK1: Casein Kinase 1; CN: 
Calcineurin; NLS: nuclear localization signal; SP: SPxx repeat; SRR: serine rich region; 
TAD: transactivation domain. Adapted and reprinted with permission from Elsevier: Li, 
H., Rao, A., & Hogan, P. G. (2011). Interaction of calcineurin with substrates and 
targeting proteins. Trends in cell biology, 21(2), 91–103. doi:10.1016/j.tcb.2010.09.011 
License: 3145420796458
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Figure 1.2 Schematic of NFAT docked to CaN
CnA: light gray, CnB: dark gray, LxVP docking site: green, CaN active site: light blue, 
PxIxIT docking site: yellow, NFAT: blue, Phosphorylations: red circles. Adapted and 
reprinted with permission from PLOS: Grigoriu, S., Bond, R., Cossio, P., Chen, J. A., Ly, 
N., Hummer, G., et al. (2013). The Molecular Mechanism of Substrate Engagement and 
Immunosuppressant Inhibition of Calcineurin. (G. A. Petsko, Ed.)PLoS Biology, 11(2), 
e1001492. doi:10.1371/journal.pbio.1001492.s007 License: Creative Commons
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Figure 1.3 Calcineurin domain structure
Structure of CaN with domains highlighted. PDBID: 1AUI.52 Catalytic domain: dark 
blue; CnB binding helix: blue; Regulatory  domain (RD): green, drawn, electron density is 
missing from crystal structure; CaM  binding region: orange rectangle, drawn, electron 
density  is missing from crystal structure;Autoinhibitory  domain (AID): red; C-terminal 
tail (CT): light gray, drawn, electron density is missing from crystal structure; Calcineurin 
B (CnB): dark gray.
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Figure 1.4 Activation of calcineurin by calmodulin 
CaN is maintained in an inactive state in the absence of CaM/calcium by the binding of 
its AID at the active site. When calcium-loaded CaM binds to the disordered regulatory 
domain (RD), the RD undergoes an ordering that  removes the AID from the active site. 
Adapted and reprinted with permission from Elsevier: Rumi-Masante, J., Rusinga, F. I., 
Lester, T. E., Dunlap, T. B., Williams, T. D., Dunker, A. K., et al. (2012). Structural basis 
for activation of calcineurin by calmodulin. Journal of molecular biology, 415(2), 307–
317. doi:10.1016/j.jmb.2011.11.008 License: 3145460588532
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a. b.
Figure 1.5 CaM structure
Calmodulin: green, MLCK CaM binding peptide: blue, calcium: red. a) Crystal structure 
of CaM in the classical calcium loaded dumbbell form. PDB ID: 3CLN.76 b) NMR 
structure of CaM bound to a peptide of a canonical CaM  binding site in  MLCK. PDB ID: 
1CDL.77
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Figure 1.6 Structure of CaM with CaMBR of CaN, 2:2 stoichiometry
Crystal structure showing two CaM molecules bound to two peptides of the CaMBR 
from CaN. One CaM molecule is shown in orange, and the other is shown in yellow. 
CaMBR peptides from CaN are shown in red. PDB ID: 2W73.70 Adapted and reprinted 
with permission from PLOS: Majava, V., & Kursula, P. (2009). Domain Swapping and 
Different Oligomeric States for the Complex Between Calmodulin and the Calmodulin-
Binding Domain of Calcineurin A. (V. Majava & P. Kursula, Eds.) PLoS ONE, 4(4), 
e5402. doi:10.1371/journal.pone.0005402.t003 License: Creative Commons
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Figure 1.7 Schematic of CaN domains and CaM binding region placement within the 
regulatory domain
Linear schematic of CaN domains is shown with the RD and AID highlighted to show the 
location of the CaMBR within the RD. Adapted and reprinted with permission from 
Elsevier: Rumi-Masante, J., Rusinga, F. I., Lester, T. E., Dunlap, T. B., Williams, T. D., 
Dunker, A. K., et al. (2012). Structural basis for activation of calcineurin by calmodulin. 
Journal of molecular biology, 415(2), 307–317. doi:10.1016/j.jmb.2011.11.008 License: 
3145460588532
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Chapter 2: Materials and Methods
Materials
All chemicals were obtained from Sigma (St. Louis, MO) and were of the highest purity, 
except where noted.
Plasmid expression vectors
The plasmid pETagHisCN containing the human αCaN A (with N-terminal His6 tag) and 
B1 genes, together forming αCaN, was obtained from Addgene (Cambridge, MA).  The 
pETCaMI expression vector was generously provided by Professor Anthony  Persechini 
of the University of Missouri at Kansas City. An E. coli codon-optimized gene for the 
human sequence RD construct was synthesized by Genscript (Piscataway, NJ). The RD 
gene has added bases coding for MWG at the N-terminus and GCGGGLE at  the C-
terminus (Figure 2.1). The extra MWG creates the methionine start codon and allows for 
protein concentration determination via the added tryptophan. The GCGGGLE creates a 
glycine linker to the His6tag in the expression plasmid, adds a cysteine for the attachment 
of maleimide fluorophores, and adds an XhoI restriction site. The RD was subcloned into 
the pET303/CT-His vector that adds a C-terminal His6 tag (Invitrogen, Carlsbad, CA) by 
using XbaI and XhoI to excise the RD gene from its original plasmid and to linearize the 
pET303/CT-His vector and ligating the RD gene to linearized pET303/CT-His. The 
subcloned gene was sequenced by ACGT inc. (Wheeling, IL) to ensure the presence and 
integrity of the gene.
Mutagenesis
CaN-A447E, CaN-A451E, CaN-A454E, RD-A447E, RD-A451E, RD-A454E, and CaM-
D3C were all created from the original gene in its expression vector using Stratagene 
QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) (Figure 2.2). RDc 
(Figure 2.3) was also created using materials from the Stratagene QuikChange II Site-
Directed Mutagenesis kit, but the primer design and PCR was performed as follows78: 
RDc was generated from the RD gene in pET303/CT-His. The deletion mutant removes 
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everything after the first three residues of the RD up to the three residues before the 
CaMBR. This is a 15 residue deletion. The primers were designed such that the reverse 
primer matches the N-terminus but has an overlap segment that  matches the beginning of 
the region after the one to be deleted. The forward primer matches the segment after the 
region to be deleted  but has an overlap segment that matches a portion of the N-terminus 
(before the deleted region) (Figure 2.4). The reaction mixtures were set up as the 
Stratagene QuikChange II Site-Directed Mutagenesis kit calls for, but the PCR was 
performed as in Table 2.1. All mutated genes were sequenced by  ACGT inc. (Wheeling, 
IL) to ensure the presence of the mutations and the integrity of the genes.
Expression and purification of recombinant CaN and CaN mutant proteins
The CaN and CaN mutant vectors were transformed into Escherichia coli BL21 (DE3) 
CodonPlus RIL cells (Agilent Technologies, La Jolla, CA) for expression as follows: 
Cells containing protein plasmid were grown overnight in 100mL Terrific Broth (TB, IBI 
Scientific, Peosta, IA) under the selection of ampicillin (amp, 75µg/mL) at 37°C with 
shaking. The following day, cultures were transferred to 900mL TB/amp and grown at 
37°C with shaking until OD600 reached ~1.5. Protein expression was induced by adding 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM  and 
grown for four hours at  37°C with shaking. After expression, cells were pelleted by 
centrifugation at 6000g for 7 minutes at 4°C. Pellets were stored at -20°C until 
purification. 
Cell pellets were thawed and resuspended in 1/40 of culture volume of lysis buffer 
(20mM Tris pH 7.5, 10mM Imidazole, 200mM NaCl, 1mM  PMSF) and one Complete 
Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, IN) was added. Lysozyme was 
added to a final concentration of 125µg/mL and cell resuspension was incubated on ice 
for 20 minutes. Cells were sonicated three times for 20sec each with 3sec on, 1sec off 
pulse and 60% amplitude. Lysate was centrifuged at 25000g for 20min at  4°C and 
0.45µm filtered before applying to a 10mL Ni-NTA column pre-equilibrated in binding 
buffer (20mM Tris pH 7.5, 10mM  Imidazole, 200mM  NaCl). Column was washed with 
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100mL of binding buffer and protein was eluted with 35mL elution buffer (20mM Tris 
pH 7.5, 2mM  CaCl2, 250mM  Imidazole, 200mM NaCl). The elution was applied to a 
CaM-Sepharose column (GE Healthcare, Piscataway, NJ) pre-equilibrated with Tris 
column buffer (20mM Tris pH 7.5, 200mM NaCl, 2mM CaCl2). The column was washed 
with 100mL of Tris column buffer and eluted with CaM-Seph elution buffer (20mM Tris 
pH 7.5, 200mM NaCl, 4mM EGTA) and collected in 15 x 1.2mL fractions. Proteins had 
their identities confirmed via mass spectrometry and purity confirmed by 14% SDS-
PAGE analysis. If necessary, protein was dialyzed into appropriate buffer using 
SnakeSkin dialysis tubing (10kDa MWCO, Pierce/Thermo) and concentrated using 
Amicon Ultra centrifugal filter units (10kDa MWCO; Millipore, Billerica, 
Massachusetts). Protein concentrations were determined using either protein absorbance 
at 280nm or using the bicinchoninic acid assay.79
Expression and purification of recombinant RD and RD mutant proteins
The RD and RD mutant vectors were co-transformed into Escherichia coli BL21 (DE3) 
cells with the pETCaM1 vector. CaM is co-expressed with RD or RD mutants and then 
removed during purification. When RD is expressed without CaM  co-expression the 
protein is degraded in cells before purification. Cells containing protein plasmids were 
grown overnight in 100mL Terrific Broth (TB, IBI Scientific, Peosta, IA) under the 
selection of ampicillin (amp, 75µg/mL) for RD and kanamycin (kan, 50 µg/mL) for CaM 
at 37°C with shaking. The following day, cultures were transferred to 900mL TB/amp 
and grown at 37°C with shaking until OD600 reached ~1.5. Protein expression was 
induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration 
of 0.5mM  and grown for four hours at 37°C with shaking. After expression, cells were 
pellet by centrifugation at 6000g for 7 minutes at 4°C. Pellets were stored at  -20°C until 
purification. 
Cell pellets were thawed and resuspended in 1/40 of culture volume of lysis buffer 
(20mM Tris pH 7.5, 10mM Imidazole, 200mM NaCl, 1mM  PMSF) and one Complete 
Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, IN) was added. Lysozyme was 
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added to a final concentration of 125µg/mL and cell resuspension was incubated on ice 
for 20 minutes. Cells were sonicated three times for 20sec each with 3sec on, 1sec off 
pulse and 60% amplitude. Lysate was centrifuged at 25000g for 20min at  4°C and 
0.45µm filtered. Urea/thiourea buffer (5M urea, 2M  thiourea, 20mM Tris, pH 7.5, 
200mM NaCl, 10mM imidazole) was added to the lysate at 3x lysate volume. The urea/
thiourea is used to separate the RD from CaM, and a combination of urea and thiourea is 
necessary  as high (8M) urea concentration alone does not separate the RD and CaM. The 
lysate is incubated in the urea/thiourea buffer at room temperature with stirring for 10 
minutes before applying to a 10mL Ni-NTA column pre-equilibrated in urea/thiourea 
buffer. 50mL 5M urea/ 2M  thiourea buffer was added to the column, and the column was 
incubated with shaking at room temperature for 30 minutes. The urea/thiourea 
concentration was decreased from 7M to 0.125M  by washing the column six times with 
25mL of urea/thiourea buffer that was diluted by half each time. The column was washed 
with 100mL of binding buffer (20mM Tris, pH 7.5, 200mM  NaCl, 10mM  imidazole) to 
remove any remaining urea/thiourea. Protein was eluted with 35mL elution buffer (20mM 
Tris pH 7.5, 2mM CaCl2, 250mM Imidazole, 200mM NaCl). The elution was applied to a 
CaM-Sepharose column (GE Healthcare, Piscataway, NJ) pre-equilibrated with Tris 
column buffer (20mM Tris pH 7.5, 200mM NaCl, 2mM CaCl2). The column was washed 
with 50mL of Tris column buffer and eluted with CaM-Seph elution buffer (20mM  Tris 
pH 7.5, 200mM NaCl, 4mM EGTA) and collected in 15 x 1.2mL fractions. Proteins had 
their identities confirmed via mass spectrometry and purity confirmed by 14% SDS-
PAGE analysis. If necessary, protein was buffer exchanged into appropriate buffer and 
concentrated using Amicon Ultra centrifugal filter units (3kDa MWCO; Millipore, 
Billerica, Massachusetts). Protein concentrations were determined using either protein 
absorbance at 280nm or using the bicinchoninic acid assay.79 
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Expression and purification of recombinant CaM and CaM mutant proteins
The CaM and CaM mutant vectors were transformed into Escherichia coli BL21 (DE3) 
cells (Agilent Technologies, La Jolla, CA) for expression as follows: Cells containing 
protein plasmid were grown overnight in 100mL Terrific Broth (TB, IBI Scientific, 
Peosta, IA) under the selection of kanamycin (kan, 50µg/mL) at 37°C with shaking. The 
following day, cultures were transferred to 900mL TB/kan and grown at 37°C with 
shaking until OD600 reached ~1.5. Protein expression was induced by adding isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5mM and grown for 
four hours at 37°C with shaking. After expression, cells were pellet by centrifugation at 
6000g for 7minutes at 4°C. Pellets were stored at -20°C until purification. 
Cell pellets were thawed and resuspended in 1/40 of culture volume of  CaM lysis buffer 
(20mM Tris pH 7.5, 2mM CaCl2, 200mM  NaCl, 1mM PMSF) and one Complete 
Protease Inhibitor Cocktail Tablet (Roche, Indianapolis, IN) was added. Lysozyme was 
added to a final concentration of 125µg/mL and cell resuspension was incubated on ice 
for 20 minutes. Cells were sonicated three times for 20sec each with 3sec on, 1sec off 
pulse and 60% amplitude. Lysate was centrifuged at 25000g for 20min at  4°C and 
0.45µm filtered before applying to a 10mL TAPP (2-trifluoromethyl-10-aminopropyl 
phenothiazine) Sepharose column pre-equilibrated with TAPP loading buffer (10mM Tris 
pH 7.5, 200mM  NaCl, 20mM CaCl2, 1mM  β-mercaptoethanol).80 The TAPP-Sepharose 
was synthesized at the Center for Structural Biology Chemistry Core Facility, University 
of Kentucky (supported in part by funds from National Institutes of Health National 
Center for Research Resources grant P20 RR020171). The column was washed with 
50mL TAPP loading buffer and the protein was eluted into 10 x 6mL fractions with 
TAPP elution buffer (10mM Tris-HCl pH 7.5, 200mM  NaCl, 10mM EGTA). Proteins had 
their identities confirmed via mass spectrometry and purity confirmed by 14% SDS-
PAGE analysis. Calmodulin was dialyzed into 10mM  ammonium sulfate for desalting 
and lyophilized. Lyophilized protein was resuspended in the appropriate buffer and 
0.2µm filtered. If necessary, protein was dialyzed into appropriate buffer using SnakeSkin 
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dialysis tubing (10kDa MWCO, Pierce/Thermo) and concentrated using Amicon Ultra 
centrifugal filter units (10kDa MWCO; Millipore, Billerica, Massachusetts). Protein 
concentrations were determined using either protein absorbance at 280nm or using the 
bicinchoninic acid assay.79
Peptides
The pCaN peptide for crystallographic studies (ARKEVIRNKIRAIGKMARVFSVLR) 
corresponding to the CaM binding region in the RD of αCaN was purchased from 
Genscript (Piscataway, NJ). pCaN peptide content was assumed to be 75% of weight and 
peptide resuspended in the appropriate buffer.  The pCaN peptide for fluorescence studies 
(WGARKEVIRNKIRAIGKMARVFSVLRGGC) corresponding to the CaM  binding 
region in the RD of αCaN was purchased from Pi Proteomics (Huntsville, AL ). The N-
terminal tryptophan was added to the native pCaN sequence for accurate peptide 
concentration determination using absorbance at 280nm and for tryptophan fluorescence 
measurements. The C-terminal cysteine was added for attachment of maleimide 
fluorophores, if necessary. The N-terminal and two C-terminal two glycines were added 
to act as a linker between the tryptophan or cysteine and remainder of the peptide. 
Modified p-RII (WGGDLDVPIPGRFDRRV[pS]VAAE), from cAMP dependent protein 
kinase regulatory subunit (type II), is the CaN substrate used in the phosphatase assays 
and was obtained from Atlantic Peptides (Scarborough, ME).81,82 The N-terminal 
tryptophan was added for accurate peptide concentration determination using absorbance 
at 280nm, and the following two glycines were added to act as a linker between the 
tryptophan and remainder of the peptide. pRII was resuspended in H2O and concentration 
was determined by peptide absorbance at 280nm. Both peptides were purified using 
reverse-phase HPLC, and their identities were confirmed using mass spectrometry.
25
Circular Dichroism
CD spectra and melts were collected at 20°C using a Jasco J-810 spectrapolarimeter 
equipped with a Peltier heating block. Protein CD spectra were obtained in buffer 
consisting of 20mM Tris, 200mM  NaCl, and 2mM CaCl2 at a pH of 7.5. Samples 
containing 15µM  of protein or, if a complex was being measured, 15µM of each protein 
were placed in a 1mm path length cuvette and CD spectra were taken. Each spectrum is 
an average of four scans at a scan speed of 50nm/min with five to six independent spectra 
taken for each sample. Errors are estimated to be no more than 3%. 
CD melts were obtained using a buffer consisting of 20mM  HEPES, 200mM NaCl, and 
2mM CaCl2 at  a pH of 7.5. Samples containing 15µM of protein or, if a complex was 
being measured, 15µM of each protein were placed in a 1mm path length cuvette and 
thermal melts were obtained with a heating rate of 1°C/min and were monitored at a 
wavelength of 222 nm with reported melts being the average of five or six scans. 
Fluorescence Labeling
To create CaM-FL (D3C-CaM with Alexa Fluor 488 label) and RD-FL-C (RD with Alexa 
Fluor 488 label) protein to be labeled was combined with an 10x molar excess of TCEP 
(Tris(2-carboxyethyl)phosphine hydrochloride), pH6.8 in 20mM  Tris pH 7.5, 200mM 
NaCl, and 2mM CaCl2 and incubated at room temperature for two hours. Alexa Fluor 488 
C5 Maleimide (dissolved in water; Invitrogen, Carlsbad, CA) was added to the protein/
TCEP at a 10:1 fluorescent label:dye ratio, and the mixture was diluted to a final volume 
of 1mL with 20mM  Tris pH 7.5, 200mM NaCl, and 2mM CaCl2. Final reaction 
concentrations: 60µM protein, 600µM  TCEP, and 600µM fluorescent label. Labeling 
reaction proceeded overnight, in the dark, at 4°C. 
CaM-FL reaction was transferred to a 3mL, 3.5kDa MWCO Slide-A-Lyzer G2 dialysis 
cassette (Pierce/Thermo) and dialyzed against 2L of 20mM Tris pH 7.5, 200mM  NaCl, 
and 2mM CaCl2 with stirring at 4°C seven times. Each dialysis proceeded for either four 
hours or overnight. RD reaction was was applied to a CaM-Sepharose column (GE 
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Healthcare, Piscataway, NJ) pre-equilibrated with Tris column buffer (20mM  Tris pH 7.5, 
200mM NaCl, 2mM  CaCl2). The column was washed with 50mL of Tris column buffer 
and eluted with CaM-Seph elution buffer (20mM  Tris pH 7.5, 200mM NaCl, 4mM 
EGTA) and collected in 15 x 1.2mL fractions. Alexa Fluor 488 concentration was 
determined by absorbance at 495nm. Protein concentration was determined by 
absorbance at 280nm with correction for fluorescent label absorption at 280nm.
Fluorescence Spectroscopy
Anisotropy of RD-FL-C (Alexa Fluor 488 label), RD-FL-N (tryptophan label), and CaM-
FL (Alexa Fluor 488 label) were measured using a K2 multifrequency phase fluorometer 
(ISS; Champaign, IL) equipped with Glan-Thompson polarizers. Anisotropies of labeled 
proteins were measured in 20mM Tris, pH 7.5, 200mM NaCl, 2mM CaCl2. The 
anisotropies of 100nM RD-FL-C ± 300nM CaM, 100nM  CaM-FL ± 300nM RD, and 
100nM CaM-FL ± 300nM pCaN were measured with excitation at 495nm and emission 
at 520nm. The anisotropies of 10µM RD-FL-N ± 30µM  CaM  and 10µM pCaN ± 30µM 
CaM were measured with excitation at 295nm and emission at 350nM. For each protein/
complex three independent samples were measured with 30 iterations for each sample.
The translational diffusion coefficients of 20nM RD-FL-C ± 100nM  CaM were 
determined by fluorescence correlation spectroscopy (FCS) using an ALBA Fluorescence 
Fluctuations Spectroscopy System (ISS, USA) fitted to an inverted Nikon, Model Ti-U 
microscope and 488 nm and 635 nm continuous wave diode lasers. Diffusion coefficients 
are the averages of three independent samples. FCS was performed by Xiaolu Zhang in 
the Department of Chemistry at the University of Kentucky.
Size-exclusion chromatography
Analytical size-exclusion chromatography (SEC) was performed on RDc, CaM, and 
CaM:RDc using a Superdex 75 10/300 GL column on an ÄKTA FPLC both from GE 
Healthcare Lifesciences (Pittsburgh, PA). The running buffer used was 20mM  Tris pH 
7.5, 200mM  NaCl, 50mM CaCl2. All proteins were buffer exchanged into running buffer 
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and 0.2µm filtered before use. Column elution was monitored at 280nm for the presence 
of protein. 100µL of 232µM  RDc was run through the column in triplicate, and 100µL of 
1.1mM CaM was run through the column in triplicate. CaM  was used at a much higher 
concentration than RDc because CaM  contains no tryptophans, but does have two 
tyrosines, making its absorbance at 280nm much lower than RDc which contains a 
tryptophan. 100µL of CaM:RDc complex was run under two different conditions: 1) 
excess RDc: 200µM RDc and 150µM CaM and 2) excess CaM: 150µM RDc and 200µM 
CaM. Gel filtration standards were purchased from Bio-Rad (Hercules, CA), and one 
18mg vial was dissolved in 0.5mL running buffer, 0.2µm filtered, and 100µL run on the 
column.
Structure determination
Crystals of the CaM:pCaN complex were grown using hanging-drop vapor-diffusion 
experiments by Emily Holbrook, NSF-REU student. Purified CaM was combined with a 
slight molar excess of pCaN and concentrated to 10 mg/ml in 10mM Tris pH 7.5, 2.3mM 
CaCl2.  Protein was mixed in a 3:1 ratio of protein:mother liquor containing 24% PEG 
1000, 20% glycerol in a final volume of 200 nL using a mosquito crystallization robot 
(TTPLabtech). Crystals formed in 2-3 weeks at 18°C. Crystals were harvested, passed 
through mother liquor supplemented with 10% glycerol, and flash frozen in liquid 
nitrogen. Diffraction data to 1.95 Å was collected at  the SER-CAT ID-22 beamline of the 
Advanced Proton Source, Argonne National Laboratories (Table 2.2). Data were 
processed using HKL2000.83 
An initial molecular replacement solution was obtained using PHASER with calmodulin 
N-terminal and C-terminal lobes (PDB=2W73) as the search model with the assistance of 
Dr. Craig Vander Kooi.84 Clear electron density for pCaN was observed and manually 
built. Iterative model building and refinement using COOT85 and Refmac586 by Tori 
Dunlap and Hou-fu Guo produced a final refined model (Table 2.2).  Molecular graphics 
were prepared using Pymol.
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Calcineurin phosphatase assays
Phosphatase assays were performed in assay buffer, 50mM Tris, pH 7.5, 100mM NaCl, 
0.5mM DTT, 0.025% NP-40, 0.5mM CaCl2 (Enzo Life Sciences, Farmingdale, NY). 
50uL reactions contained 30nM CaN or mutant, 90nM CaM, and 0-800µM p-RII as 
substrate. Reactions were initiated with p-RII and proceeded for 7min at 30°C. Reactions 
were terminated and free phosphate was detected by addition of 100uL Biomol Green 
Reagent (Enzo Life Sciences), incubation for 20min, and absorbance measured at 620nm. 
Each assay was performed in five replicates. Kinetic constants were determined by  fitting 
substrate vs initial velocity plots to the Michaelis-Menton equation using KaleidaGraph 
software.
Copyright © Victoria Beth Dunlap
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                 380              390   
MWGSDDELGSEEDGFDGATAAAR    
            400              410
KEVIRNKIRAIGKMARVFSVLRE
       420              430
ESESVLTLKGLTPTGMLPSGVLS 
  440              450              460
GGKQTLQSATVEAIEADEAIKGF
SPQHKITGCGGGLEHHHHHH
Figure 2.1 Sequence of the RD construct
RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: gray. Extraneous 
sequence was added for protein expression and purification purposes.
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                 380              390   
MWGSDDELGSEEDGFDGATAAAR    
            400              410
KEVIRNKIRAIGKMARVFSVLRE
       420              430
ESESVLTLKGLTPTGMLPSGVLS 
  440              450              460
GGKQTLQSATVEAIEADEAIKGF
SPQHKITGCGGGLEHHHHHH
Figure 2.2 Sequence of the RD portion of CaN and RD mutants
The RD portion of the sequence for the following CaN or RD constructs is shown: CaN-
A447E, CaN-A451E, CaN-A454E, RD-A447E, RD-A451E, RD-A454E. The underlined 
alanines are the amino acids that have been mutagenized to glutamates in the constructs 
listed. RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: gray. 
Extraneous sequence was added for protein expression and purification purposes.
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                          400              410   
MAGTAAARKEVIRNKIRAIGKMARVFSVLR    
        420               430              440
EESESVLTLKGLTPTGMLVLSPSGGGKQTL
         450              460              
QSATVEAIEADEAIKGFSPQHKITGWGGGL 
 
EHHHHHH
Figure 2.3 Sequence of the RDc construct
Sequence of RDc construct is shown. The sequence is the same as RD3 except there is a 
15 residue deletion at the location of the arrow (the 15 residues have been removed from 
the sequence). RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: 
gray. Extraneous sequence was added for protein expression and purification purposes.
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Figure 2.4 Schematic of primer design to create the RDc deletion mutant
The primers were designed such that the reverse primer matches the N-terminus (core 
segment) but has an overlap segment that matches the beginning of the region after the 
one to be deleted. The forward primer matches the segment after the region to be deleted 
(core segment) but has an overlap segment that matches a portion of the N-terminus 
(before the deleted region). Melting temperature of the core segments should be ~60° and 
melting temperature of the overlap segments should be ~30°C.
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Table 2.1: PCR cycles for generation of the RDc mutant
#cycles Temp Time
1 95C 30s
25 95C 30s
55C 1min
72C 6min
1 72C 10min
1 6C end
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Table 2.2: Data collection and refinement statistics
Data collection 
Beamline APS 22-ID 
Space group C2 2 21 
Wavelength 0.9792
Unit-cell parameters 59.408, 73.934, 162.382 
Unique reflections 15796
Completeness (%) 91.1 (69.6) 
Resolution (Å) 1.95 (2.02-1.95) 
Rmerge (%) 9.8 (37.5) 
Redundancy 5.5 (3.2) 
I/σ(I) 14.4 (3.37) 
Refinement 
Resolution Limits (Å) 19.12-1.95 
# reflections/# to compute Rfree 14985/801 
R (Rfree) 23.0 (28.1) 
# protein residues 166
# solvent molecules 58
# calcium molecules 4
Ramachandran 
Most favored 97.6
Allowed 2.4
Disallowed 0
RMS deviation 
Bond, Å 0.007
Angle, ° 1.064
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Chapter 3: Disorder to order in the regulatory domain of calcineurin
Introduction
Intrinsically disordered proteins (IDP) are those that do not possess well-defined three-
dimensional structures in aqueous solution.87,88 This also includes intrinsically disordered 
regions (IDRs), disordered segments of polypeptide chain within an otherwise well-
ordered protein. IDRs are extremely common and play crucial roles in human biology, 
including roles in transcription, signaling pathways, and the immune system.87,89-92 As 
such, IDRs are implicated in a number of human disease states such as cardiovascular 
disease,93 protein aggregation diseases,90 and cancer.94 
IDRs exist in conformational ensembles as, by definition, they do not have well-defined 
three-dimensional structure, but this does not mean that they  are devoid of any structure. 
Disorder is a continuum from extended polypeptide chain to a molten globule state. Babu 
et al. have defined four types of disordered states along the disorder continuum that are 
useful for characterizing IDRs, from more disorder to less disorder: unstructured and 
extensive disorder, restricted ensemble of conformations, partially populated secondary 
structure and linear peptide motif, and regulated partial or complete folding upon binding.
95 Where in this continuum an IDR exists is highly  dependent on its sequence. In general, 
IDRs have a low number of hydrophobic residues and a higher polar/charged residue 
content as compared to well ordered proteins, but the net charge of the protein affects the 
nature of the disorder.87-89,92,96 Sequences enriched in polar amino acids and deficient in 
hydrophobic residues form compact, globular conformations, closer to the “more 
ordered” end of the continuum.95,97,98 As the net charge per residue increases, there is a 
transition from globular to loosely  packed ellipsoidal coils, a “less ordered” 
conformation.95,99,100
The very  important calcium signaling protein calmodulin (CaM) appears to take 
advantage of IDRs at the “regulated partial or complete folding upon binding” end of the 
disorder spectrum. 101 CaM has ~300 known binding targets66 including important 
enzymes such as calcineurin,73 CaM kinase I,102 and smooth muscle myosin light  chain 
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kinase.103 When CaM binds a target it  induces, in most but not all cases, α-helical 
structure in the CaM binding region (CaMBR).77,104 Radivojac et al.101 employed a 
bioinformatics approach to predict that unbound CaMBR sequences are often within 
disordered regions, and we have previously  demonstrated that these regions often have a 
propensity towards α-helicity.69
The serine/threonine protein phosphatase calcineurin (CaN) is regulated by CaM  in this 
folding-upon-binding manner.73 CaN is important in several developmental processes as 
well as learning and memory, skeletal muscle growth, and immune system activation.4 
Inappropriate CaN regulation is implicated in Alzheimer’s disease6, Down syndrome7, 
and cardiac hypertrophy.8,9 CaN is a heterodimer composed of an A-chain and a B-chain. 
The ~60-kDa A-chain consists of the catalytic domain, B-chain binding helix, regulatory 
domain (RD), an autoinhibitory domain (AID), and a C-terminal tail (CT) (Figure 3.1).55 
The CaM  binding region (CaMBR) is a 24 residue stretch within the regulatory domain. 
The 19-kDa B-chain is structurally  homologous to CaM and binds four calcium ions.57 
There are three dominant CaN isoforms: the neuron specific αCaN, ubiquitous βCaN, and 
the testes specific γCaN.58 Here, we discuss αCaN, and further use of CaN will refer to 
αCaN.
Previous proteolysis work by Yang et  al. and Manalan et al., the crystal structure of CaN, 
and sequence analysis work all suggest  that the RD may be disordered.52,56,71,72 Rumi-
Masante et  al. used CD spectroscopy and hydrogen-deuterium exchange mass 
spectrometry  (HXMS) to show that a portion of CaN corresponding to the RD-AID-CT is 
disordered in the absence of CaM  but gains α-helical structure upon CaM binding.73 The 
CaM induced structure occurs in both the CaMBR and in the region C-terminal, prior to 
the AID. Given that CaM  seems to prefer to bind IDRs and induce folding, that the RD-
AID-CT undergoes a disorder-to-order transition upon CaM binding, and that the RD-
AID-CT has a low net charge per residue of -0.04, it is likely  that the RD of CaN exists in 
a  disordered but compact, globular conformation that  gains persistent secondary 
structure upon CaM binding. 
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In this work, we investigate the nature of the disorder and structure of the RD in the 
absence and presence of CaM. We use only the RD of CaN (instead of the RD-AID-CT) 
because this is the region that contains the CaMBR, and Rumi-Masante et al. 
demonstrated that the structure gained upon CaM  binding is only  in this region (Figure 
3.1).73 We performed CD spectroscopy on the RD ± CaM  to ensure that we see the same 
conformational change upon CaM binding in the RD that Rumi-Masante et al observed in 
the RD-AID-CT.73 Additionally, we employed fluorescence anisotropy to probe the 
rotational diffusion of the RD ± CaM using an RD construct  with a fluorophore on the C-
terminus (Alexa Fluor 488), RD-FL-C, and using an RD construct with a fluorophore on 
the N-terminus (tryptophan), RD-FL-N. The tryptophan added to the N-terminus of the 
RD is the only tryptophan in the molecule. We also measured the translational diffusion 
of the RD ± CaM using RD-FL-C in fluorescence correlation spectroscopy  (FCS). While 
the RD likely exists as this compact, globular ensemble, our CD, anisotropy, and FCS 
experiments demonstrate that the RD undergoes further collapse upon CaM binding. 
CaM binding causes the RD to gain persistent α-helical secondary structure in which the 
RD:CaM complex has a similar hydrodynamic radius to that of the RD or CaM alone.
Results
The RD of CaN is devoid of persistent secondary structure, but gains α-helix upon 
CaM binding
It was shown by Rumi-Masante et. al. via circular dichroism (CD) spectroscopy and H/D 
exchange mass spectrometry (HXMS) that the RD-AID-CT alone is disordered, and there 
was no detectable gain of structure in the AID or CT upon CaM  binding to the RD-AID-
CT fragment.73 To analyze the secondary structure of the RD we obtained CD spectra of 
the RD alone. The spectrum is consistent with that of an unstructured polypeptide chain 
(Figure 3.2). CD spectra of CaM alone is highly  α-helical, as evidenced by the strong 
minima at 208nm and 222nm. This is consistent with the mostly  α-helical CaM  seen in 
crystal structures.76,105-107 
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When CaM is combined with an equimolar amount of a peptide corresponding to the 
CaMBR of CaN (pCaN) there is an increase in helical content as is expected for CaM 
binding to and inducing helix in a CaM-binding peptide (Figure 3.2). CaM binds to CaN 
with a KD ~1pM, therefore the 15µM of both CaM  and pCaN used should result in 
essentially  all protein being bound. Upon addition of an equimolar amount of RD to CaM 
there is an increase in α-helix that  is greater than the increase seen with CaM:pCaN 
(Figure 3.2). This indicates that the RD gains α-helix upon CaM  binding, both in the 
CaMBR and in additional RD sequence. These data are similar to that  seen by  Rumi-
Masante et.al. for CaM, pCaN:CaM, RD-AID-CT, and RD-AID-CT:CaM.73 
pCaN:CaM anisotropy
The anisotropy of the tryptophan of pCaN was measured in the absence and presence of 
CaM (Figure 3.3a, Table 3.1). The anisotropy  of pCaN alone was 0.033 ± 0.010 and 
increases to 0.182 ± 0.017 with the addition of CaM. This is consistent with previously 
reported anisotropy measurements of a tryptophan containing peptide from MLCK 
binding to CaM, ~0.057 for the MLCK peptide alone to ~0.180 when CaM was added.103 
For comparison, the anisotropy of CaM-FL (Alexa Fluor 488 label) was measured in the 
absence and presence of pCaN (Figure 3.3a, Table 3.1). The anisotropy of CaM  alone was 
0.150 ± 0.012 and was 0.151 ± 0.002 with pCaN. The consistency of CaM anisotropy 
with or without pCaN is to be expected given that the increase in size that comes from 
binding of the 3.3kDa pCaN to the 16.7kDa CaM is small. Also, calcium loaded CaM 
exists as an extended conformational ensemble that typically binds by wrapping around 
its target peptide. This collapse of CaM around its target decreases the apparent volume 
of CaM which increases the rotational diffusion, decreasing anisotropy. The KD of CaM 
binding to CaN is ~1pM.44 With our measurements using 10µM  of tryptophan fluorescent 
proteins, 100nM of Alexa Fluor 488 fluorescent proteins, and a 3x excess of the non-
fluorescent protein in complexes, essentially all fluorescent protein should be bound in 
the cases where complexes are measured.
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Fluorescence anisotropy is a measurement of the rotational diffusion of a fluorophore. 
When measuring the anisotropy of a protein labeled with a fluorophore the anisotropy is 
influenced by both the rotational diffusion of the protein that  the fluorophore is attached 
to and the rotational diffusion of the fluorophore, independent of the protein. We attribute 
the larger anisotropy of pCaN:CaM  as compared to pCaN:CaM-FL to differences in the 
rotational diffusion of the fluorophores, independent of the proteins. When CaM  binds 
pCaN, pCaN forms an α-helix that is buried within CaM, and the pCaN tryptophan is at 
its N-terminus. Conversely, the Alexa Fluor 488 is attached to the N-terminal end of CaM 
which is not buried and is likely more flexible. Therefore, the pCaN tryptophan would 
experience less rotational freedom than the CaM  Alexa Fluor 488, increasing its 
anisotropy.
RD:CaM anisotropy
The anisotropy of RD-FL-C (Alexa 488 label, C-terminus) is 0.091 ± 0.002 whereas the 
anisotropy  of CaM-FL is 0.150 ± 0.004 (Figure 3.3b, Table 3.1). The lower RD-FL-C 
anisotropy  is due to the smaller RD size (MW=11.8 compared to CaM MW=16.7kDa), 
but it  also suggests that  the fluorophore has more rotational freedom from being in a 
disordered environment, as one would expect for the disordered RD. The RD-FL-C 
anisotropy  increases to 0.118 ± 0.008 with the addition of CaM. Comparatively, the 
anisotropy  of CaM-FL bound to RD is 0.172 ± 0.04 (Figure 3.3b, Table 3.1). The increase 
in anisotropy for either protein alone (RD-FL-C:CaM = 0.027, RD:CaM-FL = 0.022) is 
small when one considers that the increase in size from single protein to complex is close 
to a doubling of size, depending on the protein being measured. This suggests that, while 
there is an increase in molecular weight due to the complexation of the two proteins, that 
increase is offset by  a collapse of both molecules. For CaM, it exists in an extended 
conformational ensemble when not bound, and wraps around the RD, decreasing its 
hydrodynamic radius. The RD exists in a disordered state that  collapses to a smaller 
hydrodynamic radius upon CaM  binding. Additionally, while both anisotropies increase 
comparably, the anisotropy of RD-FL-C:CaM is considerably  lower than that of 
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RD:CaM-FL. This suggests that, while binding to CaM  increases the anisotropy of RD-
FL-C, the fluorophore remains in a more disordered environment as compared to the 
fluorophore on CaM when CaM-FL binds RD.
We also measured the anisotropy of RD-FL-N (tryptophan label, N-terminus) with and 
without CaM as a comparison to the anisotropy  of RD-FL-C with the fluorescent label on 
the C-terminus. The anisotropy of RD-FL-N is 0.096 ± 0.020; comparable to the 0.091 ± 
0.002 of RD-FL-C. When CaM is added, the anisotropy of RD-FL-N increases to 0.149 ± 
0.044 which is a considerably  larger increase than RD-FL-C upon CaM  addition, a 0.053 
increase for RD-FL-N compared to a 0.027 increase for RD-FL-C. This suggests that  the 
N-terminal end of the RD becomes more restricted upon CaM binding as compared to the 
C-terminal end of the RD.  This is expected given that the N-terminal tryptophan is 20 
residues from the beginning of the CaMBR whereas the C-terminal Alexa Fluor 488 label 
is 55 residues from the end of the CaMBR. 
Translational diffusion of RD ± CaM
We obtained diffusion coefficients for RD-FL-C ± CaM using fluorescence correlation 
spectroscopy  (FCS). The diffusion coefficient for RD-FL-C is 77.4 ± 0.6µm2/sec and for 
RD-FL-C:CaM is 74.4 ± 9.2µm2/sec (Table 3.1). The translational diffusion for both the 
RD-FL-C alone and complexed with CaM are essentially  equivalent, within the error of 
the measurement. While the protein concentrations used for FCS are low, 20nM RD-FL-
C ± 100nM CaM; we are confident that the RD-FL-C and CaM are bound as the KD for 
CaM:CaN binding is ~1pM.44 The equivalent  translational diffusion coefficients for RD-
FL-C alone and bound to CaM  are consistent with our anisotropy  data, suggesting that 
the complex, while larger in molecular weight, has a similar hydrodynamic radius to 
either CaM or RD alone.
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Discussion
Intrinsically disordered regions (IDRs) are sections of polypeptide chain within ordered 
proteins that do not possess stable three-dimensional structure in aqueous solution.87,88 
However, these regions are not devoid of structure but  exist as conformational ensembles 
whose shape can fall anywhere from extended polypeptide to molten globule. The 
sequence of an IDR impacts its disordered shape.95 IDRs that are enriched in polar amino 
acids but devoid in hydrophobic residues tend to form more ordered, compact, globular 
conformations whereas those IDRs with high a high net charge per residue form less 
ordered, loosely packed ellipsoidal coils.95,97-100 The calcium signaling protein 
calmodulin takes advantage of IDRs that fall on the more ordered “regulated partial or 
complete folding upon binding” end of the disorder spectrum.69,101 CaM has a tendency  to 
bind disordered regions, wrapping around the CaMBR of the target sequence and 
inducing α-helix.  77,104 Calcineurin is one such protein that CaM  binds. The CaMBR of 
CaN is in its regulatory domain (RD). Studies by Rumi-Masante et  al. showed that the 
RD-AID-CT of CaN is disordered but gains α-helix upon CaM binding in both the 
CaMBR and the region of the RD that is C-terminal to the CaMBR.73 In this work we 
have explored the nature of the disorder and structure in the RD of CaN with and without 
CaM.
We performed CD studies on the RD with and without CaM  to ensure that  the RD alone 
behaves similarly to the RD-AID-CT studied by Rumi-Masante et al., as their HXMS 
studies showed that the gain in structure the RD-AID-CT experiences upon CaM binding 
occurs only in the RD.  73 Our CD studies demonstrated that  the RD is unstructured and 
gains α-helix upon CaM binding. This is consistent the work Rumi-Masante et al. 
performed on the RD-AID-CT.73 Thus, the RD does undergo a disorder-to-order 
transition upon CaM binding, gaining persistent α-helical secondary structure. 
We did anisotropy studies with CaM, RD, and pCaN, a peptide corresponding to the 
CaMBR of CaN, to investigate the rotational diffusion of the RD in its disordered state 
and when bound to CaM. Anisotropy studies showed a large increase in the tryptophan 
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anisotropy  of pCaN upon CaM binding. This is expected given the binding of a 16.7 kDa 
protein such as CaM to a small  3.3kDa peptide like pCaN. The anisotropy change is 
consistent with that of CaM binding to a peptide of the CaMBR of MLCK.103 The 
anisotropy  of CaM  with a fluorophore bound (CaM-FL, Alexa Fluor 488), however, does 
not change upon binding pCaN. Canonically, CaM  exists in an extended conformational 
ensemble that collapses and wraps around its target  peptide upon binding. Therefore, 
upon binding pCaN, the molecular weight of the complex is not  much larger than CaM-
FL alone and the apparent hydrodynamic radius is smaller than that of CaM-FL alone, 
resulting in no change in observed anisotropy.  Any change in CaM anisotropy upon RD 
binding would be due to the effects of the RD sequence outside of the CaMBR.
An increase in anisotropy corresponds to a decrease in rotational diffusion of the 
fluorophore. This can be due to an increase in hydrodynamic radius of the molecule to 
which the fluorophore is bound, such as when the fluorophore bound molecule binds 
another protein, as is the case when pCaN is bound by CaM. Alternatively, increased 
anisotropy  can be the result of a decrease in the rotational diffusion of the fluorophore 
within the protein environment, such as when a fluorophore is bound to a disordered 
region and that region becomes structured. These two factors both impact the anisotropy 
of the RD in the absence and presence of CaM. We find that RD-FL-C has a lower 
anisotropy  as compared to CaM-FL. This is partially due to the smaller size of the RD 
(11.7 kDa for the RD vs 16.7kDa for CaM), but is also due to the increased rotational 
diffusion of the fluorophore caused by  the flexibility of the disordered RD. The 
anisotropy  of CaM-FL increases upon binding RD as does the anisotropy of RD-FL-C 
upon binding CaM. The increases in anisotropy are comparable (RD-FL-C:CaM = 0.027, 
RD:CaM-FL = 0.022) and small for a change from 16.7kDa for CaM  and 11.7kDa for RD 
to a 28.4kDa complex, suggesting that the complex has a hydrodynamic radius similar to 
either protein alone. However, the anisotropy of RD-FL-C bound to CaM is considerably 
smaller than CaM-FL bound to RD, indicating that the fluorophore on RD-FL-C still 
exists in a somewhat disordered environment in the RD-FL-C:CaM complex. 
43
We also measured the tryptophan anisotropies of RD-FL-N (tryptophan label, N-
terminus) with and without CaM  for comparison to RD-FL-C (Alexa Fluor 488 label, C-
terminus) anisotropies. The two RD species had the same anisotropy in the absence of 
CaM, but RD-FL-N:CaM had a larger anisotropy  compared to RD-FL-C:CaM. This 
suggests that the tryptophan of RD-FL-N becomes more restricted upon CaM  binding 
than the Alexa Fluor 488 on RD-FL-C does. HXMS data from Rumi-Masante et  al. 
demonstrated that  the structure in the RD gained upon CaM binding occurs both in the 
CaMBR and in the region C-terminal to the CaMBR.73 The structure gained in the region 
C-terminal to the CaMBR is an amphipathic helix termed the distal helix. It is 
hypothesized that the distal helix folds back onto CaM  where its hydrophobic face 
interacts with CaM, and this hairpin-like chain reversal removes the AID from the 
catalytic site, activating CaN (Dunlap  et al., submitted). Disruption of the hydrophobic 
face of the distal helix diminishes CaN activity. However, the Tm for the helix is ~40°C, 
indicating that the helix is only  partially stable in in vivo. Our RD-FL-C anisotropy data 
also suggest that the distal helix may be unstable as the change in anisotropy from RD-
FL-C to RD-FL-C:CaM suggests that the Alexa Fluor 488 label at the C-terminal end is 
still in a flexible environment when CaM binds.
FCS measurements were taken to determine the translational diffusion coefficients of 
RD-FL-C alone and complexed with CaM. The diffusion coefficients for RD-FL-C with 
and without CaM were the same within the error of the experiment. This is consistent 
with our anisotropy studies with RD-FL-C with CaM and CaM-FL with RD. The increase 
in anisotropies from individual protein to complex was small, indicating little change in 
apparent hydrodynamic radius. The absence of significant  change in the translational 
diffusion coefficient of RD-FL-C upon CaM binding also suggests that the hydrodynamic 
radius of the complex is similar to that of RD-FL-C alone. While FCS experiments are 
conducted at very  low protein concentrations (20nM  RD-FL-C ± 100nM CaM), we are 
confident that RD-FL-C is binding CaM  under these conditions as the KD for CaM:CaN 
binding is ~1pM.44 
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It was previously  shown that the RD of CaN is disordered but gains structure upon CaM 
binding.73 Our CD studies have confirmed the disorder of the RD and the gain of α-helix 
seen in the RD by Rumi-Masante et al.73 Given the low net charge per residue of the RD, 
one would expect it to exist as an ensemble of disordered but compact, globular 
conformations.95,99,100  The RD likely exists as this compact, globular ensemble, but our 
CD, anisotropy, and FCS experiments demonstrate that the RD undergoes further collapse 
upon CaM binding, gaining persistent α-helical secondary structure in which the 
RD:CaM complex has a similar hydrodynamic radius to that of the RD or CaM alone.
Copyright © Victoria Beth Dunlap
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Figure 3.1: Calcineurin domain structure and RD construct
a. Structure of CaN with domains highlighted. PDBID: 1AUI.52 b. Schematic of the RD 
constructs used. Orange indicates the CaM  binding region. The blue circle is the location 
of the tryptophan in RD-FL-N, and the yellow circle is the location of the Alexa Fluor 
488 in RD-FL-C. The black line indicates the region of the RD that is protected in HXMS 
upon CaM binding as shown by Rumi-Masante et al.73
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Figure 3.2: RD, CaM, pCaN CD spectra
Far UV CD spectra collected at 20°C for RD, CaM, pCaN complexed with CaM, and RD 
complexed with CaM.
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Figure 3.3: Fluorescence anisotropies
Fluorescence anisotropy measurements for a. pCaN, pCaN + CaM, CaM-FL, and CaM-
FL + pCaN; b. CaM-FL, CaM-FL + RD, RD-FL-C, RD-FL-C + CaM, RD-FL-N, RD-
FL-N + CaM. Error bars indicate the standard deviation across measurements. pCaN: 
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peptide of the CaM binding region, CaM-FL: D3C-CaM with Alexa Fluor 488 covalently 
linked to C3, RD-FL-C: RD with Alexa Fluor 488 covalently linked to a cysteine at the 
C-terminus, RD-FL-N: RD whose anisotropy was measured using the tryptophan at the 
N-terminus.
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Table 3.1: Anisotropies and diffusion coefficients of pCaN, CaM, RD, and complexes
Anisotropy Diffusion Coefficient (µm2/sec)
pCaN 0.033 ± 0.010 -
pCaN + CaM 0.182 ± 0.017 -
CaM-FL 0.150 ± 0.012 -
CaM-FL + pCaN 0.151 ± 0.002 -
CaM-FL + RD 0.172 ± 0.04 -
RD-FL-C 0.091 ± 0.002 77.4 ± 0.6
RD-FL-C + CaM 0.118 ± 0.008 74.4 ± 9.2
RD-FL-N 0.096 ± 0.020 -
RD-FL-N + CaM 0.149 ± 0.044 -
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Chapter 4: Stoichiometry of the calcineurin regulatory domain-calmodulin 
complex
Introduction
Calcineurin (CaN) is a calcium/calmodulin (CaM) activated serine/threonine 
phosphatase. It  was originally identified by Wang and Desai,1 Watterson and Vanaman,2 
and Klee and Krinks3 as an inhibitor of the CaM activated cyclic 3’,5’-nucleotide 
phosphodiesterase. These groups demonstrated that CaN binds to, and thereby  depletes, 
CaM in brain tissue, preventing activation of cyclic 3’,5’-nucleotide phosphodiesterase 
by CaM. 
Since its discovery, CaN has been shown to play roles in cardiac, vasculature, and 
nervous system development.4 CaN signaling is also necessary for learning and memory, 
skeletal muscle growth, and immune system activation.4 Because of its roles in these 
varied signaling systems inappropriate CaN regulation has been implicated in a number 
of pathological states including Alzheimer’s disease,6 Down syndrome,7 and cardiac 
hypertrophy.8,9 Additionally, CaN’s ability  to dephosphorylate and activate the nuclear 
factor of activated T-cells (NFAT) family of transcription factors makes it the target of the 
immunosuppressant drugs FK506 and cyclosporin A.4,5 
CaN is a heterodimer composed of a 57-61kDa A chain (CnA) and a 19kDa B chain 
(CnB). CnA is composed of the catalytic domain, CnB binding helix, regulatory domain 
(RD), autoinhibitory domain (AID), and C-terminal tail (CT) (Figure 4.1a).55 CnB is a 
calcium binding EF hand protein that is structurally homologous to CaM. While CnB can 
bind up to four calcium ions, it  is constitutively  bound to CnA, regardless of calcium 
concentrations.57 There are three CaN isoforms: αCaN is found primarily in neurons, 
βCaN is ubiquitous, and γCaN is testes specific.58 The pCaN and CaN regulatory  domain 
fragment (RDc) used in this work are from αCaN. Sequence numbering and use of “CaN” 
refers to αCaN. 
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Under resting calcium conditions, CaN is maintained in an inactive state by its 
autoinhibitory domain (AID) bound to CaN’s catalytic site. When calcium levels rise, 
calmodulin (CaM) binds calcium and then binds to the calmodulin binding region 
(CaMBR) of CaN, located in the regulatory domain (RD) (Figure 4.1).56 In the absence of 
calcium/CaM  the RD is disordered, and CaM binding to CaN causes an ordering in the 
RD that removes the AID from CaN’s catalytic site, activating the enzyme. 73
While there are several classes of sequences that CaM binds to, calcium loaded CaM 
preferentially  binds to basic, amphipathic, α-helical sequences (BAA sequences).44,66,67 In 
some cases, as with CaN, the CaM target sequence is disordered but prone to α-helicity.69 
Typically, when CaM binds BAA sequences, the CaM central linker helix becomes 
flexible and its two CaM  lobes wrap around the target to form a compact ellipsoid 
(Figure 4.2 a,b).66,67
Ye et al. have published crystal structures of CaM  bound to a peptide of the CaMBR of 
CaN (Figure 4.1).74,75 We refer to the peptide of the CaMBR of CaN as pCaN. In these 
structures the CaM:pCaN complex exists as a 2:2 structure in which the N-terminal lobe 
of one CaM  molecule and the C-terminal lobe of a second CaM  molecule interact with a 
pCaN peptide. The remaining C- and N-terminal lobes of the two CaM  molecules, 
respectively, interact with a second pCaN molecule (Figure 4.2c). The interaction occurs 
such that  a pCaN peptide and two CaM  lobes interact in an antiparallel fashion. The N-
terminal lobe of a CaM molecule interacts with the C-terminus of pCaN, and the C-
terminal lobe of a second CaM molecule interacts with the N-terminus of pCaN. While 
this 2:2 structure is different than the canonical “wrap-around” structure that generally 
occurs with calcium loaded CaM binding to a BAA sequence, the 2:2 structure does 
mimic a wrap-around structure when one considers only  one half of the structure: an N-
terminal CaM lobe and a C-terminal CaM lobe wrapped around a pCaN peptide.
Majava et al. also published a CaM:pCaN structure in which the stoichiometry  is 2:2 that 
is very similar to the structures by  Ye et al.70 With the high resolution of their structure 
(1.45Å) they are able to note that residues in both the hydrophobic pockets of CaM and 
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the peptide have double conformations. In addition, the authors point out that low B-
factors are seen at  the exterior of the complex as compared to the interior of the complex, 
suggesting that crystal contacts are what stabilize the crystal form. Majava et al. also 
performed small-angle X-ray  scattering (SAXS) and size-exclusion chromatography 
(SEC) on the CaM:pCaN complex. The SAXS data could only  be fit to a 1:1 wrap-around 
model, and the SEC showed a 1:1 complex. Ye et al. performed native-gel analysis on 
CaM:pCaN and SEC on a CaM:pCaN fusion protein. Both techniques showed species 
corresponding to 1:1 and 2:2 molecular weights, with the 1:1 species being the dominant 
form.75 The work by both Ye et al. and Majava et al. suggest CaM:pCaN can exist as both 
a 1:1 and 2:2 complex in solution, with a 1:1 complex being the dominant species, but is 
2:2 in crystal structures.70,74,75
O’Donnell et al. have done extensive hydrodynamic work on CaM  bound to pCaN from 
βCaN (pCaNβ).44 The CaMBR of βCaN differs from that of αCaN by  only one residue: 
V395 in αCaN is I404 in βCaN. The sequence numbers are different due to an N-terminal 
extension in CnA of βCaN. O’Donnell et al. used analytical gel chromatography to 
determine the Stokes radii, sedimentation velocity studies to determine the sedimentation 
coefficients, and NMR to determine 15N T2 relaxation times of CaM, CaM:pCaNβ, and 
CaM:melittin. Melittin is a peptide that  CaM  is known to form a 1:1 complex with.
44,108,109 For each hydrodynamic experiment, CaM:pCaNβ and CaM:melittin were 
identical, within the errors of the experiments. Compared to calcium-loaded CaM  alone, 
the CaM:peptide complexes had values consistent with a smaller hydrodynamic volume, 
suggesting that, in solution, CaM:pCaNβ forms a collapsed, wrap-around 1:1 complex 
similar to CaM:melittin. 
In addition to hydrodynamic experiments, O’Donnell et al. used various NMR 
experiments to examine some of the side-chain interactions in the CaM:pCaNβ complex. 
They  showed that P43 in the N-terminal lobe of CaM has an NOE with F419 at the C-
terminal end of pCaNβ, the only aromatic in the peptide. This demonstrates that, in 
solution, CaM binding to pCaNβ occurs in an antiparallel fashion such that the N-
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terminal lobe of CaM  binds the C-terminus of the peptide and the C-terminal lobe of 
CaM binds the N-terminus of the peptide. All of the hydrodynamic and NMR data on 
CaM:pCaNβ put  forth by O’Donnell et al. are consistent with a collapsed, wrap-around 
1:1 structure.
Taken together, the experiments performed by Ye et al., Majava et  al., and O’Donnell  et 
al. suggest that CaM:pCaN exists as a 2:2 complex in solid-state crystallographic studies 
but is predominantly  a 1:1 complex in solution.44,70,74,75 In this work, we attempt to 
reconcile the 2:2 solid-state complex and the 1:1 solution complex by  doing 
crystallography on CaM:pCaN and analytical size-exclusion chromatography on 
CaM:RDc. RDc is a construct using the C-terminal portion of the RD from the beginning 
of the CaM binding region to the beginning of the AID (Figure 4.1b). We used 
CaM:pCaN for the crystallographic work  so that our structure would be comparable to 
the previous structures, and we used CaM:RDc for the size-exclusion chromatography to 
determine if using a larger portion of CaN would impact the stoichiometry  of CaM 
binding in solution.
Results
Size-Exclusion Chromatography
We performed size-exclusion chromatography (SEC) on RDc, CaM, and the CaM:RDc 
complex to determine the stoichiometry  of the complex and to discover if the inclusion of 
more of CaN than just the CaMBR used in previous SEC and crystallography studies 
would impact the stoichiometry of the complex. In SEC runs of RDc alone and CaM 
alone, RDc eluted at 11.87mL, and CaM eluted at 11.60mL, where the elution volume is 
the volume at which the protein absorbance (280nm) peak was maximal (Figure 4.3a). 
Comparing SEC of RDc and CaM to the SEC standards, we can see that both proteins 
elute between the 44kDa standard (ovalbumin, 10.54mL) and the 17kDa standard 
(myoglobin, 12.28mL) which is seemingly inconsistent with their molecular weights of 
10.4kDa and 16.7kDa, respectively (Figure 4.3a, Table 4.1). However, in previous work 
of CaM binding to a peptide of the CaM binding region of CaN (pCaN) it was shown that 
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the elution volume for the complex is actually  lower than for that of CaM alone.70 This is 
attributed to the extended nature of calcium-loaded CaM  in the absence of a binding 
partner. The molecular weight standards are globular in nature whereas CaM is more 
ellipsoidal, giving it  a larger hydrodynamic radius than what would be expected for a 
globular protein of the same size. This is consistent  with the decrease in stokes radius of 
CaM bound to peptide as compared to CaM alone seen by O’Donnell, et al.44 RDc alone 
also appears at an elution volume that would suggest it has a higher molecular weight 
than 10.4kDa. A construct of the RD-AID-CT of CaN has been shown to be disordered in 
solution.73 The RDc would also be disordered and, similarly  to CaM  alone, extended in 
conformation. Thus, RDc alone runs at a lower elution volume than expected due to its 
extended nature compared to the globular nature of the standards.
The absorbance of CaM at 280nm is much stronger than RDc due to the use of a much 
higher concentration of CaM  (1.1mM CaM  vs 0.232mM RD). This was done to improve 
the CaM absorbance at 280nm since CaM has only two tyrosines and no tryptophans. The 
tryptophan on RDc is extraneous sequence added to the construct for concentration 
determinations. Additionally, in the CaM SEC trace there is a small peak around 8mL that 
we attribute to protein aggregate as it elutes within the same volume as the 670kDa 
standard (thyroglobulin, 8.06mL) (Table 4.1).
We performed SEC on the CaM:RDc complex under conditions of excess RDc 
([RDc]=200µM, [CaM]=150µM) and excess CaM ([RDc]=150µM, [CaM]=200µM) 
(Figure 4.3b). The complex eluted at 11.21mL under both conditions. In the complex with 
excess RDc SEC trace there is a peak at 11.83mL, consistent with unbound RDc. There is 
a shoulder on the CaM:RDc peak in the SEC trace of the complex with excess CaM  that 
is consistent with unbound CaM, but whose elution volume could not be determined. The 
unbound CaM absorbance at 280nm in the excess CaM  trace is much lower than the 
unbound RD absorbance at 280nm in the excess RD trace due to the absence of 
tryptophans in CaM. Additionally, in the SEC trace of the complex with excess CaM 
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there is a small peak around 8mL as there was in the CaM alone SEC trace. As with the 
CaM alone SEC trace, we attribute this peak to aggregate.
The CaM:RDc complex elutes at 11.21mL which is between the 44kDa standard 
(ovalbumin, 10.54mL) and the 17kDa standard (myoglobin, 12.28mL), consistent with a 
1:1 complex whose molecular weight would be 27.1kDa (Figure 4.3b, Table 4.1). If the 
complex were 2:2 with a molecular weight of 54.2kDa the elution volume for the 
complex would need to be between 8.70mL and 10.54mL, the elution volumes of the 
158kDa and 44kDa standards (ɣ-globulin and ovalbumin, respectively) (Table 4.1). There 
is a slight peak at ~10mL that would be consistent  with a 2:2 complex, but this peak is 
smaller than even the aggregate seen at 8mL and much, much smaller than the 1:1 
complex peak. Therefore, in our SEC studies, the CaM:RDc has a 1:1 stoichiometry.
Crystal structure of the CaM:pCaN complex
The CaM:pCaN complex was crystallized in 24% PEG 1000, 20% glycerol and the 
structure was determined at 1.95Å. Initial model building was done using the N-terminal 
and C-terminal lobes of CaM from one of the CaM  molecules in the 2:2 structure from 
Majava et al. (PDB=2W73).70 Crystallography data and refinement statistics can be found 
in Chapter 2, Table 2.2. The final structure reveals a 1:1 complex of CaM:pCaN, not a 2:2 
structure like those determined by  Ye et al. and Majava et al (Figure 4.2d).70,74,75 The 
difference in stoichiometry between our 1:1 structure and the 2:2 structures is likely due 
to the differences in crystal growing conditions. The crystals obtained by Ye et. al. were 
grown in 0.2M ammonium phosphate, 0.1M  citrate acid (pH 4.5) and 20% (w/v) PEG 
3350; and the crystals from Majava et  al. were grown in 30% PEG 400, 200 mM KCl, 
and 100 mM Tris (pH 8.5).70,74,75
The structure maintains the antiparallel binding seen in those structures as the N-terminal 
lobe of CaM interacts with the C-terminal end of pCaN, and the C-terminal lobe of CaM 
interacts with the N-terminal end of pCaN. Additionally, many of the CaM:pCaN 
intermolecular interactions are similar in our 1:1 structure and the 2:2 structures. I396 and 
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I400 of pCaN interact with M124 and F92 of CaM, respectively, in all structures (Figure 
4.4). I403 of pCaN interacts with A88, V91, and V35 in CaM in all structures as well. 
Finally, R408 of pCaN forms salt bridges with E83 and D80 of CaM  in all structures. 
Surprisingly, these R408:E83 and R408:D80 interactions occur between pCaN and the 
linker helix of CaM that is ridged in the 2:2 complexes and bent in our 1:1 complex.
Calcium-loaded CaM has two major hydrophobic pockets that aromatic residues of BAA 
sequences typically interact with. These are termed the FLMMn and FLMMc pockets: 
F19, L32, M51, and M71 in the N-terminal lobe of CaM and F92, L105, M124, and 
M144 in the C-terminal lobe of CaM, respectively (Figures 4.4, 4.5).44,110 In BAA 
sequences with one aromatic residue, the aromatic is usually buried in the FLMMc 
pocket, and in sequences with more than one aromatic residue one usually resides in each 
FLMM  pocket. The only  aromatic residue in pCaN is F410, and it interacts with FLMMn 
in the 2:2 complexes (Figure 4.5b).70,74,75 There are other, non-aromatic hydrophobic 
contacts that pCaN makes with FLMMc in the 2:2 structures (noted above), but no 
residues are buried in the pocket (Figure 4.4b). In our 1:1 CaM:pCaN complex F410 of 
pCaN is not buried in either FLMM  pocket, but instead ring-stacks with P43 of CaM. 
O’Donnell et al (Figure 4.7).44 observed an NOE between F419 of pCaNβ (corresponding 
to F410 of pCaN) and P43 of CaM, supporting evidence for the the F410:P43 ring 
stacking we observe in our 1:1 complex. This NOE is not consistent with F410 binding in 
the FLMMn pocket.
Instead of an aromatic in either FLMM pocket, our 1:1 CaM:pCaN complex shows M406 
of pCaN buried in the FLMMn pocket, contacting all of the residues of the tetrad (Figure 
4.5a). This appears to be the major stabilizing interaction for CaM:pCaN in our complex. 
Similar to the 2:2 structures, I396 and I400 of pCaN interact with M124 and F92 of 
FLMMc, but no residues are buried in the pocket (Figure 4.4a).
Discussion
Ye, et  al. and Majava et al. have determined crystal structures of CaM:pCaN that 
demonstrate a 2:2 complex wherein the N-terminal lobe of one CaM molecule and the C-
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terminal lobe of a second CaM  molecule interact with a pCaN peptide.70,74,75 The 
remaining C- and N-terminal lobes of the two CaM  molecules, respectively, interact with 
a second pCaN molecule (Figure 4.2c). The interaction occurs such that a pCaN peptide 
and two CaM lobes interact  in an antiparallel fashion. The N-terminal lobe of a CaM 
molecule interacts with the C-terminus of pCaN, and the C-terminal lobe of a second 
CaM molecule interacts with the N-terminus of pCaN. While these structures are 
obviously very different from the typical wrap-around binding that calcium-loaded CaM 
displays with BAA sequences similar to CaN’s, they do mimic the wrap-around binding 
in that an N-terminal lobe of CaM and a C-terminal lobe of CaM appear to wrap-around 
the pCaN peptide.
Majava et. al performed SAXS and SEC on CaM:pCaN in solution, finding a 1:1 
complex in both cases.70 Ye et. al. also performed SEC as well as native-gel analysis on 
the CaM:pCaN complex and found both a 2:2 species and a 1:1 species, with the 1:1 
complex being the dominant form.74,75 In addition, O’Donnell et al. did extensive 
hydrodynamic and NMR studies on CaM  with pCaN from βCaN (pCaNβ) and found only 
a 1:1 complex.44 These studies, combined with the 2:2 crystal structures, suggest that 
CaM:pCaN exists as a 2:2 complex in solid-state crystallographic studies but is 
predominantly a 1:1 complex in solution.44,70,74,75 It seems that while a small population 
of 2:2 complexes exists in solution, the dominance of the 2:2 complex in crystal 
structures is likely due to the stabilizing effects of crystal contacts between complexes, as 
described by Majava et. al.70 
We sought to reconcile the 2:2 solid-state complexes and the 1:1 solution complexes by 
doing crystallography on CaM:pCaN and analytical size-exclusion chromatography on 
CaM:RDc, where RDc is a construct using the C-terminal portion of the RD from the 
beginning of the CaM binding region to the beginning of the AID (Figure 4.1b). 
In both our SEC and crystallographic data we observe a 1:1 complex. In SEC, when CaM 
and RDc are run together, we see a peak that elutes between the volumes where the 
44kDa and the 17kDa standards elute, consistent with a complex whose molecular weight 
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would be 27.1kDa (Figure 4.3b, Table 4.1). If the complex were 2:2 with a molecular 
weight of 54.2kDa the elution volume for the complex would need to be between 
8.70mL and 10.54mL, the elution volumes of the 158kDa and 44kDa standards. This is 
similar to what Ye et al. observe in their SEC and native-gel analysis, however, we see no 
evidence of a 2:2 complex in our SEC.74,75 Majava et al. and O’Donnell et al. also 
observed only 1:1 complexes in their CaM:pCaN solution studies.44,70
We performed SEC on CaM in complex with RDc, a piece of the regulatory domain of 
calcineurin that is 56 residues longer than the 24 residue pCaN alone. The RDc construct 
was used to determine if the increased sequence space would have any impact on the 
stoichiometry of the complex. The extra length does not affect the complex stoichiometry, 
but does change the behavior of the complex in SEC. Upon addition of the pCaN peptide 
to CaM, Majava et al. observed a shift in the CaM SEC peak to a later elution volume 
than that of CaM alone. This is counterintuitive as the addition of the peptide increases 
the molecular weight, thereby one expects a shift  to an earlier elution volume. However, 
CaM’s extended dumbbell shape in the absence of ligand causes it  to elute at a volume 
consistent with a larger molecule. Therefore, when CaM wraps around the pCaN peptide, 
the apparent molecular weight observed by  SEC decreases because its hydrodynamic 
radius has actually decreased.70,111 
In our SEC studies, the elution volume of the CaM:RDc complex is shifted to an earlier 
elution volume as compared to CaM  alone, as is generally the case upon an increase in 
molecular weight. The difference in our SEC as compared to the SEC done by  Majava et 
al. is due to the additional residues in the RDc. 
The full RD of CaN is known to be disordered in the absence of CaM  but gains structure 
upon CaM  binding.73 We used RDc, as opposed to the full RD, in our studies because 
Rumi-Masante et al. had shown that the structure gained in the RD upon CaM binding 
occurs C-terminal to the CaMBR. RDc is the majority of the RD but lacks 15 residues N-
terminal to the CaMBR (Figure 4.1), a region shown by Rumi-Masante et al. not to gain 
structure.73  In our SEC the CaM:RDc complex elutes at an earlier volume than either 
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CaM or RDc alone, as expected. However, the decrease in elution time is not as much as 
one would expect  for essentially  doubling the molecular weight of the complex compared 
to either component alone. This suggests that, not only does CaM wrap around the RDc, 
causing an apparent decrease in hydrodynamic radius, but the disordered RDc also 
collapses upon CaM  binding. We have previously shown that the α-helical structure 
gained in the RD upon CaM  binding is an amphipathic helix that diminishes CaN activity 
when its hydrophobic face is disrupted. We hypothesized that, because the hydrophobic 
face of the helix would need another hydrophobic surface to interact with, this helix folds 
back upon CaM  in a hairpin-like chain reversal upon CaM binding. The hairpin-like 
chain reversal of this helix onto CaM is consistent with our SEC results that suggest a 
collapse in RDc structure upon CaM binding (Dunlap et al., submitted).
In addition to our SEC studies, our crystallographic structure determination of the 
CaM:pCaN complex demonstrates a 1:1 stoichiometry (Figure 4.2d). Previous 
CaM:pCaN crystal structures have all had 2:2 stoichiometry.70,74,75 We have shown that a 
1:1 stoichiometry  also occurs in the crystallographic solid-state. Majava et al. pointed out 
that low B-factors are seen at the exterior of their crystal complex as compared to the 
interior of the complex, suggesting that crystal contacts stabilize the crystal form. In our 
CaM:pCaN structure the low B-factors are observed on the inside of the complex, 
particularly along the pCaN peptide and in the N-terminal lobe of CaM at the FLMMn 
residues, where M406 of pCaN is buried. Therefore, the 1:1 complex seems to be 
stabilized by the interaction of M406 with the FLMMn tetrad, not by crystal contacts.
While several of the intermolecular CaM:pCaN contacts are the similar between our 1:1 
complex and the 2:2 complexes, there is one striking difference: the interaction of M406 
of pCaN with the FLMMn pocket of CaM (Figure 4.5). This interaction is unique to the 
1:1 complex not only  because it is different from the 2:2 complexes, but also because it  is 
different than other known BAA:CaM  interactions. When CaM  interacts with BAA 
sequences with one aromatic residue, the aromatic is buried in the FLMMc pocket, and in 
sequences with more than one aromatic residue one usually resides in each FLMM 
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pocket.44,110 In pCaN, the only  aromatic residue is F410. In the 2:2 complexes, F410 is 
buried in the FLMMn pocket, not the FLMMc pocket (Figure 4.5a). In our 1:1 complex 
F410 is not buried in either pocket. M406 occupies the FLMMn hydrophobic pocket, and 
the FLMMc pocket is unoccupied, though several small hydrophobic residues on pCaN 
interact with the FLMMc tetrad (Figure 4.4a). F410 ring-stacks with P43 of CaM, an 
interaction that is consistent with an NOE seen by O’Donnell et al. between F419 of 
pCaNβ (F410 in pCaN) and P43 of CaM (Figure 4.7).
In their 2:2 crystal structure, Ye et al. observe interactions between M72 and M76 of CaM 
with V409 and F410 of the pCaN peptide. They also observe salt bridges between R408 
of the peptide and D80 and E83 of CaM.75 These interactions occur between the peptide 
and the central linker helix of CaM (Figure 4.6b). In the 2:2 structures, the central linker 
helix is one, extended helix, allowing one CaM molecule to interact with to pCaN 
peptides. However, in our 1:1 structure we observe the linker helix bent  as two helices 
with a loop  region in between, allowing CaM  to wrap around pCaN. Ye et al. argue that 
the interactions they see between pCaN and the central linker helix of CaM stabilize the 
extended form of the linker helix, thereby  stabilizing the 2:2 structure. 75 In our 1:1 
structure, we do not observe the interactions between M72/M76 of CaM and V409/F410 
of pCaN. The shortest distance is from M76 to V409, and that distance is ~10Å. F410 is 
on the opposite side of the pCaN helix from the two CaM  methionines. However, our 1:1 
structure does exhibit the salt-bridges between R408 of pCaN and D80/E83 of CaM 
(Figure 4.6a). As these salt bridges are observed in both our 1:1 structure and the 2:2 
structures, it is unlikely that they  serve to stabilize the extended CaM central linker helix 
seen in the 2:2 structures.
From the SEC we performed on CaM:RDc and the crystal structure we determined of 
CaM:pCaN, we conclude that both exist as a 1:1 complex. Solution and hydrodynamic 
studies by Ye et  al., Majava et al., and O’Donnell et al. have shown that the predominate 
form of CaM:pCaN in solution is the 1:1 species. Our SEC with CaM:RDc confirms this 
and also demonstrates that an increase in the pCaN sequence to encompass the majority 
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of CaN’s RD does not alter the stoichiometry of the complex. The crystal structure of 
CaM:pCaN we determined is also of a 1:1 complex; this is in contrast to the previously 
reported 2:2 CaM:pCaN structures. However, our 1:1 complex of one CaM molecule 
wrapping around one pCaN peptide is consistent with the NMR work and extensive 
hydrodynamic work done by O’Donnell et al. as well as previously published CaM:BAA 
structures.44,110 Our 1:1 CaM:pCaN crystal structure and SEC data for the CaM:RDc 
complex strongly suggest that a single CaM  molecule is responsible for binding to and 
activating CaN.
Copyright © Victoria Beth Dunlap
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        420               430              440
EESESVLTLKGLTPTGMLVLSPSGGGKQTL
         450              460              
QSATVEAIEADEAIKGFSPQHKITGWGGGL 
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Figure 4.1: Calcineurin domain structure and RDc construct
a. Structure of CaN with domains highlighted. PDBID: 1AUI.52 b. Sequence of RDc 
construct RD: green, CaMBR: orange, portion of AID: red, extraneous sequence: gray. 
Extraneous sequence was added for protein expression and purification purposes.
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Figure 4.2: CaM and CaM:target peptide structures
a. Structure of calcium loaded CaM; 3CLN.76 b. Structure of CaM  bound to smMLCK 
CaMBR; 1CDL.104 c. 2:2 structure of CaM bound to pCaN; 2R28 75 d. 1:1 structure of 
CaM bound to pCaN; structure solved in this work. CaM: green, calcium: red, CaMBR 
peptide: blue
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Figure 4.3: CaM, RDc size-exclusion chromatography
Size-exclusion chromatography traces of a. CaM alone and RDc alone and b. CaM:RDc 
complex in excess of RD or excess of CaM. In each graph, the vertical lines with 1, 2, 3, 
and 4 above them indicate the elution volume of the standards listed in Table 4.1.
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Figure 4.4: FLMMc binding pocket interactions
FLMMc binding pocket interactions in a. 1:1 structure of CaM bound to pCaN; structure 
solved in this work. b. 2:2 structure of CaM  bound to pCaN; 2R28 75 c. Structure of CaM 
bound to smMLCK CaMBR; 1CDL.104 CaM: green, CaMBR peptide: blue.
66
Figure 4.5: FLMMn binding pocket interactions
FLMMn binding pocket interactions in a. 1:1 structure of CaM bound to pCaN; structure 
solved in this work. b. 2:2 structure of CaM  bound to pCaN; 2R28 75 c. Structure of CaM 
bound to smMLCK CaMBR; 1CDL.104 CaM: green, CaMBR peptide: blue.
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Figure 4.6: pCaN R408 salt bridges with CaM D80 and E83
Salt bridge interaction between R408 of pCaN and D80, E83 of CaM in a. 1:1 structure 
of CaM bound to pCaN; structure solved in this work. b. 2:2 structure of CaM  bound to 
pCaN; 2R28 75 CaM: green, CaMBR peptide: blue.
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Figure 4.7: pCaN F410 and CaM P43 ring stacking  
Ring stacking interaction between F410 of pCaN and P43 of CaM in the 1:1 structure of 
CaM bound to pCaN; structure solved in this work. CaM: green, CaMBR peptide: blue.
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Table 4.1: Size exclusion chromatography standards run on the Superdex 75 10/300 GL 
column
Standard Molecular Weight (kDa) Elution Volume (mL)*
1. Thyroglobulin (bovine) 670 8.06
2.  ɣ-globulin (bovine) 158 8.70
3.  Ovalbumin (chicken) 44 10.54
4.  Myoglobin (horse) 17 12.28
*Elution volume is the volume at which the protein absorbance (280nm) was maximal
70
Chapter 5: The distal helix in the regulatory domain of calcineurin is 
important for calcineurin-regulatory domain stability and calcineurin 
function
Introduction
The calcium signaling protein calmodulin (CaM) is important in numerous signaling 
pathways and is known to have approximately three-hundred binding targets.66 Among 
these targets are the calmodulin activated kinases such as CaM kinase I (CaMKI), CaM 
kinase II (CaMKII), CaM kinase kinase (CaMKK), and myosin light chain kinase 
(MLCK).112 CaM activated kinases possess an autoinhibitory domain (AID) that  occludes 
the catalytic site, rendering the kinase inactive.  When cellular calcium levels rise CaM 
binds four calcium ions and then binds the kinase at a site just C-terminal to the AID, the 
CaM binding region (CaMBR), causing a conformational change that removes the AID 
from the catalytic site, activating the kinase (Figure 5.1).113
In contrast to the CaM activated kinases, there is only one known CaM  activated 
phosphatase, the serine/threonine phosphatase calcineurin (CaN).1-3 CaN is involved in 
several developmental processes including formation of the cardiac, vasculature, and 
nervous systems.4 CaN is also necessary  for learning and memory, skeletal muscle 
growth, and immune system activation.4 As such, inappropriate CaN regulation has been 
implicated in pathological states such as Alzheimer’s disease6, Down syndrome7, and 
cardiac hypertrophy.8,9 Arguably, CaN’s most well known target is the nuclear factor of 
activated T-cells (NFAT) family  of transcription factors.4 CaN dephosphorylation of 
NFAT reveals a cryptic nuclear localization signal that allows it to move to the nucleus 
and initiate a gene program for the activation of T-cells. Because of this immune system 
involvement CaN is the target of immunosuppressant drugs.5 Despite its physiological 
importance, CaN regulation at the molecular level is still poorly understood but differs 
significantly from the CaM activated kinases.
CaN is a heterodimer composed of an A-chain and a B-chain. The ~60-kDa A-chain 
houses the catalytic domain, B-chain binding helix, regulatory domain (RD), an 
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autoinhibitory domain (AID), and a C-terminal tail (CT).55 The CaM  binding region 
(CaMBR) is a 24 residue stretch within the regulatory domain (Figure 5.2). The 19-kDa 
B-chain is structurally  homologous to CaM and binds four calcium ions.57 There are three 
dominant CaN isoforms: the neuron specific αCaN, ubiquitous βCaN, and the testes 
specific γCaN.58 Here, we discuss αCaN, and further use of CaN will refer to αCaN. 
Similar to the CaM activated kinases, CaN has an AID that blocks the catalytic site until 
calcium-loaded CaM  binds.58 However, unlike the kinases, CaN’s CaM  binding region is 
N-terminal to the AID and separated from it by 52 residues (Figure 5.1). CaN’s CaMBR 
is located  in the regulatory domain (RD) of CaN (Figure 5.2). Trypsin digests and other 
hydrolysis experiments by Manalan and Klee, and Yang and Klee, respectively, 
demonstrated that the RD is readily hydrolyzed, showing that  it  is flexible and accessible 
in nature.58,71 In the structure of full length CaN the electron density for the RD and C-
terminal tail (CT) are missing suggesting that  these regions are highly mobile.52 
Additionally, Romero and Dunker noted that the sequence of the RD gave it the potential 
to be disordered.72 The trypsin digests performed by Manalan and Klee also suggested 
that the RD of CaN undergoes a large conformational change  upon CaM binding as the 
highly  unprotected RD becomes protected from trypsin digest when CaN is preincubated 
with CaM.71 Surprisingly, this potentially disordered RD is 95 residues long, whereas the 
CaM binding site is ~24 residues in length, suggesting that CaM  binding induces 
conformational changes outside of the CaMBR.
Work by Rumi-Masante et al. showed by H/D exchange mass spectrometry and circular 
dichroism spectroscopy  that a fragment corresponding to CaN’s RD, AID, and CT (RD-
AID-CT) is disordered in the absence of CaM, though the AID is well-ordered in full-
length, inactive CaN.73 The RD portion of this fragment contains the CaM  binding region 
and the 52 residues that separate it from the AID. Canonically, CaM’s two lobes wrap 
around its target site and induce α-helix in that sequence. How then does CaM activate 
CaN with its CaMBR and AID 52 residues apart  and with those 52 residues being 
disordered? 
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Rumi-Masante et al. also showed that upon CaM  binding, ~50 residues within the RD 
become protected from H/D exchange and that the RD gains approximately fifty residues 
of α-helicity.73 About half of these residues reside in the CaMBR while the remainder are 
C-terminal to the CaMBR, residing between it and the AID (Figure 5.2b).  The high 
protection and α-helicity of the CaMBR when CaM is bound is expected given the very 
tight binding between CaM  and CaN (KD ~1pM) and the manner in which CaM typically 
binds its targets.44 The protection and helicity in the region between the CaMBR and 
AID, suggested by RD protection in Manalan and Klee’s CaN/CaM  trypsin digests and 
confirmed by  Rumi-Masante et al, suggests a larger scale structuring than just the 
sequence CaM directly binds.71,73
Examination of the protected area between the CaMBR and AID reveals that residues 441 
to 459 could form an amphipathic α-helix (Figure 5.2c). It is unlikely  that a helix in this 
region would be an extension of the helix formed at the CaMBR upon CaM binding as 
the region between the CaMBR and this proposed helix is populated with glycines and 
prolines, residues known to be unfavorable in α-helices (Figure 5.2b).114 An amphipathic 
helix in this region would imply  the need for the hydrophobic face of the helix to interact 
with another hydrophobic region, however we know from Rumi-Masante et. al. that CaM 
bound RD-AID-CT does not interact with the remainder of CaN and that the only  regions 
in the RD-AID-CT to gain significant secondary  structure upon CaM binding is the 
CaMBR and part of the region between it and the AID.73 Therefore, we hypothesize that 
an amphipathic helix in the region between the CaMBR and AID would interact with the 
surface of the remainder of the RD:CaM  complex when CaM is bound to the CaMBR of 
CaN. The end of this proposed helix is seven residues from the beginning of the AID. If it 
forms and folds back upon RD:CaM when CaM binds the RD, this could provide the 
necessary  energy to remove the AID from the catalytic site. We will refer to this possible 
helix as the distal helix. In this work, we explore the nature and importance of the 
structure and function of this putative distal helix in the RD of CaN.
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Results
RD:CaM secondary structure is similar to that of the RD-AID-CT:CaM
To investigate CaM  induced structure and a possible distal helix in the region C-terminal 
to the CaMBR we created a construct consisting of only the RD of CaN (Figure 5.2b). It 
was shown by Rumi-Masante et. al. via circular dichroism (CD) spectroscopy  and H/D 
exchange mass spectrometry (HXMS) that there was no detectable gain of structure in the 
AID or CT upon CaM binding to the RD-AID-CT fragment.73 To analyze the secondary 
structure of the RD we obtained CD spectra of the RD alone. The spectrum is consistent 
with that of an unstructured polypeptide chain (Figure 5. 3a). 
An equimolar mixture of CaM and a 24-residue peptide corresponding to the CaMBR of 
CaN (pCaN) yields a spectrum with increased α-helix as compared to CaM alone, as is 
evident from the more negative minima of CaM:pCaN at 208nm and 222nm, indicators 
of α-helix (Figure 5.3a). This increase in helicity is expected for CaM  binding and 
inducing helix in its target. However, an equimolar mixture of CaM and the RD 
demonstrates that the RD:CaM complex has greater helical content than the pCaN:CaM 
complex (Figure 5.3a). These data are similar to that seen by Rumi-Masante et.al. for 
CaM, pCaN:CaM, RD-AID-CT, and RD-AID-CT:CaM.73
CaM induced RD structure is less stable than pCaN:CaM
Thermal melts of pCaN:CaM and RD:CaM  from 10°C to 95°C were obtained monitoring 
CD at 222nm, the wavelength associated with minima in CD spectra caused by α-helices. 
The pCaN:CaM  melt reveals no melting transitions, indicating that the pCaN:CaM 
complex is stable to at least  95°C. The melt of RD:CaM, however, shows a melting 
transition with Tm~40°C (Figure 5.3b). The major sequence difference between 
pCaN:CaM  and RD:CaM lies with the addition of the region C-terminal to the CaMBR 
(Figure 5.2b), thus the melting transition seen in RD:CaM is consistent with the melting 
of a helix in this region.
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Disruption of the hydrophobic face of the putative distal  helix alters CaM induced 
secondary structure
The hydrophobic face of the putative distal helix is composed of a leucine, isoleucine, 
and three alanines (Figure 5.2c). We created three RD mutants, RD-A447E, RD-A451E, 
and RD-A454E, that would disrupt the hydrophobic face but not necessarily  prevent the 
formation of a helix as glutamates are charged but have high helical propensities.114 The 
CD spectra of these mutants demonstrate that  they are unstructured polypeptide chains 
similar to wild-type RD (Figure 5.4a). 
In contrast, addition of equimolar CaM to the RD mutants yields CD spectra that have 
helical content more similar to that of pCaN:CaM, not RD:CaM  (Figure 5.4b).  The 
similarity of the RD mutant:CaM spectra to the pCaN:CaM  spectrum indicates that 
secondary  structure in the region between C-terminal to the CaMBR has been disrupted 
by the alanine to glutamate mutations. However, the RD mutant:CaM spectra have 
slightly stronger 222nm minima than pCaN:CaM, with RD-A454E being the strongest, 
suggesting that they may have some residual distal helix.
Disruption of the hydrophobic face of the putative distal  helix alters CaM induced 
helix stability
Thermal melts of the RD mutants RD-A447E, RD-A451E, and RD-A454E, with CaM 
were obtained, monitoring the CD at 222nm from 10°C to 95°C as for pCaN:CaM  and 
RD:CaM above. Consistent with the CD spectra (Figure 5.4b), the RD mutants with CaM 
have more strongly negative signals than pCaN:CaM  at the beginning of the melt, with 
RD-A454E being the strongest (Figure 5.4c). This is indicative of more α-helix in the 
mutants with CaM  than pCaN:CaM. However, all the mutants have signals approaching 
that of pCaN by the end of the melts. Wild-type RD:CaM has a stronger helical signal 
than any  of the mutants with CaM or pCaN:CaM, demonstrating its increased helicity in 
the region C-terminal to the CaMBR. Despite its weakened helical signal as compared to 
RD:CaM, RD-A454E:CaM  does have a melting transition. The Tm for this melting could 
not be obtained due to the absence of a native baseline for the RD-A454E:CaM melt. The 
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weaker helical signal of RD-A454E:CaM compared to RD:CaM  combined with the 
presence of a melting transition suggests that the RD-A454E retains a partial distal helix, 
more than that of the other mutants, but the helix is diminished as compared to wild-type 
RD. 
Disruption of the hydrophobic face of the putative distal helix diminishes CaM 
activated CaN activity
To investigate the impact of the disruption of the hydrophobic face of the putative distal 
helix on CaN dephosphorylation kinetics we created the same three alanine to glutamate 
mutations in full-length CaN as we did in the RD: CaN-A447E, CaN-A451E, and CaN-
A454E. The CaM induced activity  of these mutants, as well as wild-type CaN, was 
assessed with a malachite green free phosphate assay using varying concentrations of p-
RII peptide from cAMP dependent protein kinase regulatory subunit (type II), a well 
characterized CaN substrate.81,82 Reactions were performed with 1:3 CaN:CaM  or CaN 
mutant:CaM. Various divalent cations are known to impact CaN’s activity in different 
ways.81 In our assays we include calcium and magnesium. Table 1 gives the kinetic 
parameters for CaN and the CaN mutants obtained under the conditions of our assay. This 
kinetic analysis of CaN and CaN mutant dephosphorylation activity reveals increased Km 
values for the CaN mutants as compared to wild-type CaN (Table 1). The increased Km 
values demonstrate that the integrity of the hydrophobic face of this putative helix is both 
important for CaN activity and also impacts CaN’s ability to bind substrate. 
Discussion
In CaM activated kinases the CaMBR is directly C-terminal to the AID (Figure 5.1).112,113 
This proximity allows  CaM to bind, causing the CaMBR to form an α-helix which 
removes the AID from the catalytic site, activating the kinase. Despite CaN having both a 
CaMBR and AID as the CaM  activated kinases do, CaM  activation of CaN cannot occur 
in the same way as the CaM  activated kinases given that the C-terminal end of the 
CaMBR is 52 residues N-terminal to the AID and these residues are disordered in the 
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absence of CaM  (Figure 5.1). 56,71,73 The intervening disordered residues seemingly 
prevent the removal of the AID from the active site when CaM binds at CaN’s CaMBR.  
Proteolytic digest work by Manalan and Klee and Yang and Klee showing that the RD is 
readily degraded by proteases; missing RD and CT electron density in the CaN structure; 
and sequence analysis by Romero and Dunker all suggested that the RD is disordered.
52,56,71,72 Additionally, Manalan and Klee’s trypsin digests of CaN preincubated with CaM 
showed that the RD became protected when CaM was bound to CaN, suggesting that the 
RD undergoes a conformational change upon CaM binding.71 Rumi-Masante, et al 
showed that the RD-AID-CT is disordered but gains structure upon CaM binding.73 This 
structure includes the expected α-helix in the CaMBR, but it  also includes one or more 
regions of helical structure somewhere between the end of the CaMBR and the beginning 
of the AID.  
In this work, we investigated a construct of the RD alone. Our CD spectra for RD and 
RD:CaM are comparable to those for RD-AID-CT and RD-AID-CT:CaM done by Rumi-
Masante, et al, confirming that the α-helix gained upon CaM binding is in the RD, not the 
AID or CT.73 We also performed thermal melts of pCaN:CaM  and RD:CaM. The thermal 
melt of pCaN:CaM shows no cooperative melting transition as pCaN:CaM is extremely 
stable (KD for CaN:CaM is ~1pM) and does not melt within the 10°C to 95°C range of 
our thermal melts.44 Therefore, the melting transition seen in the RD:CaM thermal melt 
must come from melting of helical structure in the RD outside of the CaMBR. Thus, 
CaM induced helical content is both in the CaMBR and the remainder of the RD (Figure 
5.3).
Upon examination of the sequence in the region of the RD C-terminal to the CaMBR, 
identified  by  Rumi-Masante et al as the region besides the CaMBR that gains structure 
upon CaM  binding, we identified a portion that plots as an amphipathic helix on a helical 
wheel projection (Figure 5.2c). 73 From this we proposed that an amphipathic helix in this 
region forms by folding its hydrophobic face onto the surface of the rest of the RD:CaM 
complex when CaM is bound to the CaMBR of CaN. We refer to this helix as the distal 
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helix. Rumi-Masante et al showed that CaM  bound RD-AID-CT does not interact with 
CaN’s catalytic domain, B-chain binding helix, or B-chain, making the remainder of the 
RD:CaM complex the only other portion of CaN that the distal helix could interact with. 
Interaction of the distal helix with the remainder of the RD:CaM  complex would create a 
hairpin-like chain reversal that could compensate for the 52 residues between the CaMBR 
and AID allowing for the removal of the AID from the catalytic site, activating CaN. This 
helix would not be an extension of the CaMBR helix as the region between the CaMBR 
and this helix contains multiple glycines and prolines, residues known to be unfavorable 
in α-helices.  
To test for the presence of the distal helix we created three RD mutants: RD-A447E, RD-
A451E, and RD-A454E (Figure 5.2). The alanine to glutamate mutations would disrupt 
the hydrophobic face of the helix but not necessarily prevent the formation of a helix as 
glutamates are charged but have high helical propensities.114 CD spectra of these mutants 
were comparable to wild-type RD showing that they are disordered, but upon CaM 
binding the helical content gained is similar to that  of pCaN:CaM, not RD:CaM (Figure 
5.4a,b). This indicates that the mutations have caused a reduction in CaM-induced helical 
content. 
Thermal melts of the RD mutants with CaM  were similar to the thermal melt of 
pCaN:CaM, demonstrating that the lost helical content is in the RD, but outside of the 
CaMBR (Figure 5.4c). Though the CD spectra and melts are closer to pCaN:CaM than 
RD:CaM, the RD-A454E:CaM   and RD-A447E:CaM complexes shows more residual 
helical content than RD-A451E:CaM. RD-A454E:CaM even has a visible melting 
transition, though a Tm could not be determined. As  A451 is central to the distal helix, 
and A447 and A454 would be nearer the N- and C-terminal limits of the helix, mutation 
of the central alanine (A451) may  disrupt the entire helix whereas mutation of the 
alanines closer to the termini (A447 and A454) may  still allow for partial formation of the 
distal helix. We also note that thermal melting of the RD showed that the distal helix’s Tm 
is ~40°C, very near physiological body temperature of 37°C, suggesting that it is not very 
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stable. Given this, the reduced helical content of the hydrophobic face mutants, and the 
absence of this helix when CaM  is not bound to CaN suggests that the helix requires that 
its hydrophobic face interact with the remainder of the RD:CaM complex in order for it 
to form.
To investigate the importance of the distal helix in CaN dephosphorylation activity, we 
created the same mutations in full-length CaN as we did in the RD: CaN-A447E, CaN-
A451E, and CaN-A454E. Performing malachite green free phosphate assays on CaM 
activated wild-type CaN and these mutants revealed increased Kms in the mutant CaNs as 
compared to wild-type (Table 1). The increased Kms demonstrate a reduced affinity  for 
substrate in the mutant CaNs. This alteration in kinetic parameters shows that the proper 
formation of the distal helix is important for CaN dephosphorylation, but it is of note that 
the mutants diminish CaN activity, they do not abolish it. The increased mutant  CaN Kms 
suggest that the AID can still bind the active site in these mutants, even in the presence of 
CaM. However, the residual activity in these mutants suggests that in the CaN mutants 
with CaM  the AID binding in the active site is not  as tight as it is in wild-type CaN 
without CaM, likely due to residual distal helix in the mutants.
Based on our alanine mutation studies we have shown that the distal helix is comprised of 
at least eight residues if A447 and A454 are considered to be the bounds of the helix. 
However, trypsin digest work by  Rumi-Masante et al shows that both K441 and K459 are 
protected from digestion, suggesting that the distal helix may extend from residue 441 to 
459, beyond the alanine limits (Figure 5.2b).73 This gives an ~19 residue helix, which is 
consistent with the helical gain seen in the region between the CaMBR and AID by 
Rumi-Masante et al. This is also consistent with our helical wheel projection (Figure 
5.2c).
We have shown that disruption of the hydrophobic face of the putative distal helix 
diminishes the helical content in this region and reduces CaN’s affinity for substrate. 
Residual CaN activity when the hydrophobic face of the distal helix is disrupted may be 
due to residual helicity of the distal helix. In light of the importance of the distal helix for 
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CaN activity, we propose the following model for CaN activation by CaM:  When CaM 
binds to the CaMBR in the RD of CaN a stretch of residues N-terminal to the AID forms 
an amphipathic α-helix, which we have termed the distal helix. The hydrophobic face of 
the distal helix must interact with another hydrophobic region on the remainder of the 
RD:CaM complex to form. This interaction creates a hairpin-like chain reversal in the RD 
that compensates for the 52 residues between the CaMBR and AID, and allows the AID 
to be removed from CaN’s catalytic site when CaM binds, activating CaN.
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Figure 5.1: Domain ordering of CaM activated kinases compared to the domain ordering 
of CaN
In CaM activated kinases, the AID is just N-terminal to the CaM binding domain, 
allowing for easy removal of the AID from the kinase active site upon CaM binding. In 
CaN, the AID is 52 residues C-terminal to the end of CaM binding domain suggesting a 
different mode of CaM activation in CaN from the kinases.
Copyright © Victoria Beth Dunlap
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Figure 5.2: Calcineurin domain structure and regulatory domain schematics
a. Structure of CaN with domains highlighted. Catalytic domain: purple; CnB binding 
helix: blue; Regulatory domain (RD): green, drawn, electron density is missing from 
crystal structure; CaM binding region: orange rectangle, drawn, electron density is 
missing from crystal structure;Autoinhibitory domain (AID): red; C-terminal tail (CT): 
light gray, drawn, electron density is missing from crystal structure; Calcineurin B (CnB): 
dark gray. PDBID:1AUI.52 b. Sequence of RD construct with distal helical region 
highlighted by the blue region and the mutated alanine residues underlined. RD: green, 
CaMBR: orange, portion of AID: red, extraneous sequence: gray. Extraneous sequence 
was added for protein expression and purification purposes. c. Helical wheel projection of 
the distal helix. The alanine to glutamate mutations made on the hydrophobic face are 
indicated. N and C mark the N-terminal and C-terminal residues of the putative helix, 
respectively.
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Figure 5.3: CD spectra and melts of RD, CaM, pCaN, and complexes 
a. Far UV CD spectra collected at  20°C for RD, CaM, pCaN complexed with CaM, and 
RD complexed with CaM. b. Thermal melts following CD signal at 222nm from 10°C to 
95°C for pCaN complexed with CaM and RD complexed with CaM.
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Figure 5.4: CD spectra and melts of RD mutants and RD mutant:CaM complexes
Far UV CD spectra collected at  20°C  for a. RD, RD-A447E, RD-A451E, and RD-
A454E as well as b. the following, each complexed with CaM: pCaN, RD, RD-A447E, 
RD-A451E, RD-A454E. c. Thermal melts following CD signal at 222nm from 10°C to 
95°C for each of the following complexed with CaM: pCaN, RD, RD-A447E, RD-
A451E, RD-A454E.
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Table 5.1: Kinetic parameters of CaN and CaN distal helix mutants for 
dephosphorylation of p-RII peptide
Km (µM) Vmax (umol min-1 mg-1)
CaN 464 ± 60 12.0 ± 0.9
CaN-A447E 478 ± 114 8.7 ± 1.2
CaN-A451E 899 ± 213 9.7 ± 1.5
CaN-A454E 589 ± 101 11.1 ± 1.1
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Chapter 6: Conclusions and future directions, a model for calcium/CaM 
regulation of CaN
Calcineurin (CaN) signaling is vitally important  for the fetal development of numerous 
tissues, necessary  for T-cell activation, and important in learning and memory. Not only is 
CaN important in human physiology, but  it is highly conserved and necessary for survival 
from yeast  to humans.4 CaN signaling is very well studied, largely  due to CaN’s role in 
the activation of the NFAT (nuclear factor of activated T-cells) family  of transcription 
factors by dephosphorylation. Because NFAT signaling in T-cells leads to activation of T-
cells, CaN has become the target of immunosupressant drugs.4,5  
CaN is a heterodimer composed of a 57-61kDa A chain (CnA) and a 19kDa B chain 
(CnB). CnA is composed of the catalytic domain, CnB binding helix (CnBBH), 
regulatory domain (RD), autoinhibitory domain (AID), and C-terminal tail (CT) (Figure 
1.3).55 It is known that at low calcium concentrations the AID resides in the catalytic site 
of CnA, keeping the enzyme inactive. When calcium levels rise, calcium loaded CaM 
binds to the CaM binding region (CaMBR) located in the regulatory domain of CnA. 
CaM binding releases the AID from the catalytic site, activating CaN.56 CnB is a calcium 
binding EF hand protein that is structurally  homologous to CaM  and is constitutively 
bound to CnA, regardless of calcium concentrations.57 
Despite being important and highly  studied, there is much we do not know about the 
protein CaN. The efforts in this body of work have focused on furthering our 
understanding of the physical aspects of calmodulin (CaM) regulation of CaN. The work 
of many who have come before us has shown that the isolated regulatory domain is 
disordered in the absence of CaM but undergoes a conformational change upon CaM 
binding that  induces α-helical structure in the RD and, in full-length CaN, removes the 
AID from CaN’s catalytic site to activate the enzyme.52,71-73,115 This knowledge brings 
with it more questions. 
A disordered protein or protein region is not devoid of all structure but exists as a 
conformational ensemble that can be anywhere from loosely packed coils to compact and 
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globular. To describe the RD of CaN as disordered only puts it  into this wide spectrum. 
Thus, we sought to discover the nature of the disorder in the RD and the change in that 
disorder upon CaM binding (Chapter 3). We examined this by  investigating the rotational 
and translational diffusions of the RD ± CaM using fluorescence anisotropy and 
fluorescence correlation spectroscopy, respectively. Our studies have shown that, given 
its low net charge per residue, the RD likely  exists as this compact, globular ensemble, 
but CD, anisotropy, and FCS experiments demonstrate that the RD undergoes further 
collapse upon CaM binding, gaining persistent α-helical secondary structure in which the 
RD:CaM complex has a similar hydrodynamic radius to that of the RD or CaM alone. 
However, a comparison of the anisotropy of RD with a label on the C-terminus vs the N-
terminus, with CaM, suggested that  C-terminus of the RD remains at least somewhat 
flexible and disordered upon CaM binding. Given what we later learned about the 
existence of the distal helix (Chapter 5) C-terminal to the CaMBR, that it is important for 
efficient CaN activity but  only partially  stable with a Tm of ~40°C, we believe that the 
apparent partial disorder remaining at the C-terminus of the RD upon CaM binding is 
likely the result of transient folding and unfolding of this helix. However, we note that the 
Tm of the helix in vivo may be higher due to the crowding conditions found in cells.
It was also noted that there remained uncertainty concerning the stoichiometry of the 
CaN:CaM  complex. Ye et  al. and Majava et  al. have published crystal structures that 
demonstrate a 2:2 complex of a peptide corresponding to the CaMBR of CaN (pCaN) and 
CaM.70,74,75 However, solution work by these groups as well as extensive hydrodynamic 
and NMR studies by O’Donnell et al. suggested the dominant stoichiometry  in solution is 
1:1, with only  a minor fraction existing as a 2:2 complex when the 2:2 complex was seen 
at all.44,70,74,75 
Without  a confirmed knowledge of the stoichiometry of the CaM:CaN complex, any 
attempt to understand the mechanism by which CaM activates CaN would be incomplete. 
We attempted to reconcile the 2:2 solid-state complex and the 1:1 solution complex by 
using x-ray crystallography to solve the structure of the CaM:pCaN complex and 
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analytical size-exclusion chromatography (SEC) on CaM:RDC, with RDC being a 
construct of the C-terminal portion of the RD from the beginning of the CaM binding 
region to the beginning of the AID. Both the SEC studies and our crystal structure 
demonstrated a 1:1 complex, with no observable 2:2 complex present. The 1:1 complex 
of one CaM  molecule wrapping around one pCaN peptide is consistent with the NMR 
work and extensive hydrodynamic work done by O’Donnell et  al. as well as previously 
published structures of CaM  binding to other basic, amphipathic α-helical peptides of the 
same CaM binding target class as pCaN.44,110 Our 1:1 CaM:pCaN crystal structure and 
SEC data for the CaM:RDC complex strongly suggest that a single CaM molecule is 
responsible for binding to and activating CaN.
We know now that CaM binds to a disordered RD with 1:1 stoichiometry, wraps around 
the CaMBR, and causes a conformational ordering in the RD that  removes the AID from 
CaN’s catalytic site, activating the enzyme. So, how does the ordering that CaM induces 
in the RD remove the AID from CaN’s active site? There are 52 residues from the end of 
the CaMBR to the beginning of the AID. If CaM bound the RD and only induced α-helix 
in the CaMBR, 52 residues would be plenty of disordered sequence space to allow the 
AID to remain bound in the active site. However, Rumi-Masante et al. showed that ~25 
residues in this region gain α-helical structure upon CaM binding.73
Examination of the protected area between the CaMBR and AID reveals that residues 441 
to 459 could form an amphipathic α-helix (Chapter 5, Figure 5.2). It would be unlikely 
for this to be an extension of the CaMBR helix as the intervening sequence is populated 
with glycines and prolines which are unfavorable in helices.114 An amphipathic helix in 
this region would imply the need for the hydrophobic face of the helix to interact with 
another hydrophobic region, and we hypothesized an amphipathic helix in the region 
between the CaMBR and AID would interact with the surface of the remainder of the 
RD:CaM complex when CaM is bound to the CaMBR of CaN. The end of this proposed 
helix is seven residues from the beginning of the AID. If it were to form and fold back 
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onto the surface of CaM in a hairpin-like chain reversal, it could provide the force 
necessary to remove the AID from the active site. 
We explored the possibility  of this helix and its function in CaN activity by creating 
mutations in the isolated RD and full-length CaN that would disrupt the hydrophobic face 
of the helix. We obtained CD spectra and melts of the WT-RD and mutants ± CaM, as 
well as performed CaN phosphatase assays on WT-CaN and mutants in the presence of 
CaM. Our work demonstrated that disruption of the hydrophobic face of what  we termed 
the distal helix diminishes the helical content in this region and reduces CaN’s affinity for 
substrate. Residual CaN activity when the hydrophobic face of the distal helix is 
disrupted may be due to residual helicity of the distal helix.
Our work has demonstrated that CaM  binds to a disordered RD with 1:1 stoichiometry 
and causes a compaction of the RD that includes the formation of the distal helix, an 
element important for efficient CaN activity. From this the question arises: Why  does the 
distal helix exist? In lower eukaryotes, such as drosophila and yeast species, the distal 
helix sequence is absent (Figure 6.1). It seems that the absence of the sequence for the 
distal helix would allow for the direct removal of the AID from CaN’s active site without 
the need for the hairpin-like chain reversal that the distal helix causes. CaM binding to 
and inducing α-helix in the CaMBR may alone provide the steric force necessary to 
remove the AID in the absence of the distal helix. Drosophila CaN is very  similar to 
human CaN both in sequence and length, but in drosophila the helical sequence is 
missing, possibly  allowing for direct removal of the AID. Many yeast  species also have a 
deletion of the distal helix sequence, however they also have an insertion in the RD, N-
terminal to the CaMBR (Figure 6.1). In Aspergillus fumigatus the insertion has several 
serine-proline motifs, the phosphorylation of which is crucial for appropriate CaN 
signaling (Juvvadi, P.R., et al., in revision).  
It seems that the variations in the RD amongst  species are added levels of CaN 
regulation. In Aspergillus fumigatus phosphorylation in the RD regulates CaN signaling, 
and in drosophila the distal helix is missing, possibly allowing for quicker, more efficient 
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activation of CaN. So, if these variations are regulatory elements, what is the regulatory 
function of the distal helix in humans? The answer may lie in the calcium binding 
abilities of CnB. 
CnB is the calcium binding subunit of CaN. It is structurally  homologous to CaN with 
four calcium binding EF-hands. CnB binds CnA in an antiparallel manner where the C-
terminal lobe of CnB binds to the N-terminal end of the CnB binding helix (CnBBH) and 
forms an interface with the catalytic domain of CnA. The N-terminal lobe of CnB binds 
to the C-terminal end of the CnBBH. The C-terminal lobe EF-hands are the high affinity 
calcium binding sites with KD ~70nM.60 The N-terminal lobe calcium affinity is ~20µM.
60 At low calcium conditions comparable to resting cellular concentrations, the C-terminal 
lobe of CnB is calcium loaded and bound to CnA. However, the N-terminal lobe of CnB 
would be devoid of calcium and partial proteolytic digests suggest that, in the absence of 
calcium binding, the N-terminal lobe does not bind the CnBBH.56 Furthermore, these 
partial proteolytic digests also show that the RD in CaN is protected from digest in the 
absence of calcium but is rapidly degraded when calcium is present.56,71 This suggests 
that a portion of the RD folds onto CnB or the CnBBH in the absence of calcium, and 
calcium binding to the N-terminal lobe of CnB causes it  to bind the CnBBH, releasing the 
RD.
Brian Perrino, who is now at the University of Nevada, Reno, created a construct 
corresponding to the RD from the end of the CaMBR to the end of the C-terminal tale, 
encompassing the distal helix and AID, AI420-511.116 When assayed with constitutively 
active CaN (CaN1-420, missing the distal helix and AID-CT) this construct is an ~five-
fold better inhibitor of CaN than the AID alone.116 Full activation of CaN requires both 
calcium binding to CnB and  calcium-loaded CaM  binding to the RD. Calcium binding to 
the CnB results in a lowered Km while CaM  binding increases the Vmax. Addition of 
calcium to CaN (in the absence of CaM) lowers the Km ~three-fold.64 Our hypothesis is 
that a portion of the RD including the distal helix interacts with CnB/CnBBH in the 
absence of calcium and is released upon calcium binding. The interaction of the distal 
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helix region with CnB/CnBBH likely blocks substrate access to the LxVP docking site 
that is located at the CnB/CnA interface. Release of the distal helix from CnB/CnBBH 
would decrease the Km of CaN (increasing CaN’s substrate affinity) by exposing the 
LxVP docking site, allowing substrate to bind. We do not discount the role of CnB in 
propagating a conformational change to the catalytic domain upon calcium binding. It is 
likely that this occurs in addition to the changes in the RD, as lower eukaryotes without 
the distal helix still require CnB for CaN function. Thus, it seems the distal helix may 
play  a calcium sensitive regulatory role in allowing substrate binding to the LxVP 
docking site. 
However, this does not fully explain the role of the distal helix in CaN regulation as we 
have seen that drosophila are missing the distal helix and have no RD insertion that could 
compensate for the missing distal helix. Why does drosophila not need the regulation 
provided by  a distal helix, as seen in humans, or an N-terminal RD insertion, as seen in 
yeast? The answer is not readily apparent, but could be addressed by examining the 
activity of wild-type drosophila CaN as well as drosophila CaN with a distal helix 
insertion or an N-terminal RD insertion, both in vitro and in cellular environments. We 
also note that the LxVP docking site that  we believe the distal helix blocks under low 
calcium conditions is not the only substrate docking site. The PxIxIT motif present in 
NFAT substrates as well others docks on CnA, opposite from the LxVP docking site 
(Chapter 1, Figure 1.2). LxVP docking seems to be important for substrate recognition, 
but the use of the PxIxIT docking site may  allow for some substrates to bind CaN even in 
low calcium conditions, giving them ready  access to the LxVP docking site when it 
becomes available.21
Our current model for calcium/CaM  activation of CaN is: at resting cellular calcium 
levels the N-terminal lobe of CnB is devoid of calcium and not bound to the CnBBH. 
This allows the distal helix region of the RD to interact with CnB/CnBBH, occluding the 
LxVP substrate docking site. When calcium levels increase, the RD is released from its 
interaction with CnB/CnBBH by the N-terminal lobe of CnB binding calcium and then 
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the CnBBH. Release of the RD from CnB/CnBBH exposes the LxVP site, allowing for 
substrate docking at this site. Calcium-loaded CaM then binds the now disordered RD, 
causing formation of the distal helix which folds upon CaM in a hairpin-like chain 
reversal. The formation and chain reversal of the distal helix removes the AID from 
CaN’s catalytic site, causing the full activation of CaN (Figure 6.2). 
Calcium binds to CaM with KDs of ~0.2µM  and ~2µM at the C-terminal and N-terminal 
lobes, respectively.117-119 The N-terminal lobe of CnB has a KD of calcium binding of 
~20µM.60 Thus, even the low affinity  calcium binding N-terminal lobe of CaM  has a 10-
fold higher calcium affinity  than the N-terminal lobe of CnB. This suggests that when the 
CnB N-terminal lobe binds calcium and then the CnBBH, releasing the RD, CaM is 
already calcium loaded and ready to bind the RD as soon as it  is available. While 
disordered proteins and regions have been shown to exist, and it has been proven that the 
disorder is often necessary for a protein’s function, it remains a mystery as to how 
disordered proteins and regions survive a cellular environment that is designed to degrade 
and dispose of misfolded and unfolded proteins. The system of RD disorder and CaM 
binding may provide insight. If CaM  is calcium loaded and ready to bind the RD as soon 
as it is released from the CnB/CnBBH, then the disorder of the RD is very transient. The 
disorder of the RD is important to allow CaM binding, but the disorder exists only for a 
short time before CaM  binding, especially given that the KD of calcium loaded CaM 
binding to CaN is ~1pM.44 Before calcium binding to the CnB, the RD is protected by 
interaction with the CnB/CnBBH, and as soon as it  is released CaM binds, and it is 
protected by interaction with CaM. Thus, transient disorder may be one mechanism by 
which the necessary disorder of some proteins is controlled in cellular environments.
Our new knowledge of the disordered nature of the isolated RD and the formation and 
possible regulatory function of the distal helix has significantly contributed to our 
understanding of CaM  activation of CaN, but it  also raises new questions. At low calcium 
levels, we hypothesize the distal helix region of the RD binds to CnB/CnBBH, occluding 
the LxVP substrate binding site. We can investigate this possibility by  obtaining a 
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fluorescently  labeled peptide corresponding to the distal helix region of the RD and 
measure the fluorescence anisotropy  of the peptide with and without CaN373, a construct 
that includes CnA up to the end of the CnBBH and CnB. This must be done in the 
absence of calcium. If the peptide binds CaN373, it may be possible to obtain an 
anisotropy  binding curve to determine the affinity of binding. We can mutate residues in 
the CnBBH and LxVP docking site and measure the anisotropy of binding of the distal 
helix peptide to these mutants for comparison to the binding of peptide to CaN373. 
Additionally, a fluorescently labeled peptide of a substrate LxVP motif could be obtained 
and its anisotropy measured with/without CaN373 and the distal helix peptide. If the 
distal helix peptide blocks the LxVP docking site, the LxVP motif peptide will not be 
able to bind CaN373 in its presence without calcium. These experiments will demonstrate 
where the distal helix peptide binds and if it occludes the LxVP binding site.
Proteolytic studies suggest that calcium binding in the N-terminal lobe of CnB causes it 
to bind the CnBBH and release the RD.56,71 Assuming the fluorescent  studies above 
reveal distal helix sequence binding to CaN373, the release of the RD can be tested by 
measuring the anisotropy of the same peptide, testing its binding to CaN373 both in the 
absence and presence of calcium. Introduction of calcium into the system should cause 
the release of the peptide, decreasing its anisotropy. Also, measurement of the binding of 
the LxVP motif peptide to CaN373 via anisotropy measurements with/without calcium 
and the distal helix peptide will reveal if release of the distal helix exposes the LxVP 
motif. Additionally, we can use site-directed mutagenesis to disrupt the calcium binding 
sites in the N-terminal lobe of CnB. This disruption should prevent CnB N-terminal lobe 
binding to the CnBBH even under high-calcium conditions. Using this CnB mutant in 
CaN373, we can determine if disrupting calcium binding changes RD binding to the 
CnBBH and if disrupting calcium binding changes LxVP motif binding.
We see that, in drosophila, the region of the RD that  contains the distal helix is simply 
missing, yet CaN signaling obviously still works in drosophila. Thus, we can make the 
distal helix deletion in human CaN, as it is in drosophila, and examine the affect that it 
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has on CaN inhibition and activity at both high and low levels. Anisotropy measurements 
with this deletion construct and the fluorescent LxVP motif peptide ± calcium would 
confirm whether or not the distal helix sequence blocks the LxVP docking site under low 
calcium conditions. Also, we can further investigate the impact of the distal helix on CaN 
activity by testing the activity of this distal helix deletion mutant with and without 
calcium/CaM. 
If the distal helix region interacts with CnB/CnBBH under low calcium conditions, it 
would become disordered when it  is released upon CnB N-terminal lobe calcium binding. 
This is suggested by previous proteolytic studies, CaN crystal structure, previous CD 
spectroscopy, and our own CD and anisotropy studies.52,56,71-73 However, these studies are 
done in vitro and the solutions used are very dilute compared to the crowded conditions 
of the cell. It is possible that the crowding of a cellular environment causes a partial 
ordering of the RD that still allows CaM  binding. As a proxy for crowding, the propensity 
for structure of the RD in the absence of CaM  can be examined by CD spectroscopy and 
fluorescence anisotropy experiments with the RD in increasing concentrations of 
osmolytes such as trimethylamine N-oxide (TMAO) and 2,2,2-trifluorethanol (TFE). TFE 
is known to induce α-helix in peptide chains with a propensity for helix whereas TMAO 
can induce general structure. The low net  charge per residue of the RD suggests that, 
while it  is disordered, it  is relatively compact and globular in shape. If the RD’s 
conformational ensemble is restricted in this way, addition of chaotropes, or denaturants, 
such as guanidine, urea, and thiourea could disrupt the compact, globular ensemble, 
affecting the CD spectra and anisotropies of the RD. Both the osmolytes and denaturants 
can be used as tools to further investigate the disordered state of the RD.
Finally, after an increase in calcium causes the N-terminal lobe of CnB to bind calcium 
and then bind to the CnBBH, releasing the RD; CaM  is then able to bind the RD, induce 
formation of the distal helix, and removal of the AID from the catalytic site, activating 
CaN. The distal helix is amphipathic which necessitates a hydrophobic surface for its 
hydrophobic face to interact with. This surface is likely on the surface of CaM, allowing 
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the distal helix to undergo its hairpin-like chain reversal that would remove the AID from 
the active site. To better understand this interaction, we must learn where on CaM the 
distal helix binds. We can attempt to grow crystals of CaM with the RDC, as this is the 
smallest piece of the RD that still includes the CaMBR and distal helix. If diffraction 
quality crystals are obtained, we can use our CaM:pCaN crystal structure for molecular 
replacement to help solve the structure and determine the distal helix placement. 
However, as we have observed through anisotropy measurements and CD melts, the 
distal helix is only partially  stable. This may make it mobile in crystal form and its 
placement on CaM unobtainable. If this is the case, we could employ NMR spectroscopy 
to determine the structure of the RDc:CaM  complex. The complex at  27.1kDa is a 
tractable size for NMR.
As we have seen CaM binds to a disordered RD with 1:1 stoichiometry  and causes a 
compaction of the RD that includes the formation of the distal helix, an element 
important for efficient CaN activity. This points to further investigation of the RD of CaN 
when calcium levels are low to determine if the distal helix region occludes the LxVP 
binding site; when calcium levels are increased but there is no CaM to observe the nature 
of the disorder in the RD with osmolytes or denaturants; and when both calcium and 
CaM are present to determine where on CaM the hydrophobic face of the distal helix 
interacts. Our studies and literature thus far have led us to this model: at resting cellular 
calcium levels the N-terminal lobe is devoid of calcium and not  bound to the CnBBH. 
This allows the distal helix region of the RD to interact with CnB/CnBBH, occluding the 
LxVP substrate docking site. When calcium levels increase, the RD is released from its 
interaction with CnB/CnBBH by the N-terminal lobe of CnB binding calcium and then 
the CnBBH. Release of the RD from CnB/CnBBH exposes the LxVP site, allowing for 
substrate docking at this site. Calcium-loaded CaM then binds the now disordered RD, 
causing formation of the distal helix which folds upon CaM in a hairpin-like chain 
reversal. The formation and chain reversal of the distal helix removes the AID from 
CaN’s catalytic site, causing the full activation of CaN (Figure 6.2). Our work on 
calmodulin activation of calcineurin has lead us to a better understanding of the 
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molecular mechanism by which this activation occurs. It  also leads us to new questions, 
the study of which will give us a better understanding of how CaN substrate recognition 
is regulated. As our understanding of CaN regulation increases we are better positioned to 
investigate and control CaN in human health, especially with respect to the use of 
immunosupressant drugs for organ and tissue transplant patients.
Copyright © Victoria Beth Dunlap
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Figure 6.1: Sequence alignment of the RD
Sequence alignment of the RD from S. cerevisiae, S. pombe, D. melanogaster, and H. 
sapien is shown. The distal helix sequence is underlined in human. Of note is the 
insertion in S. cerevisiae and S. pombe in the region N-terminal to the CaM binding 
domain and the deletion of the distal helix in all non-human species shown.
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Figure 6.2: Model for the activation of CaN by calcium/CaM
From left to right: at low calcium levels, the CnB N-terminal lobe is unbound by calcium 
and does not bind the CnBBH, allowing the RD to interact  with this region. An increase 
in calcium causes the CnB N-terminal lobe to bind calcium and then the CnBBH, 
releasing the regulatory domain. The disordered domain is now available for calcium-
loaded CaM to bind. CaM  binding induces formation of a distal helix that allows for 
removal of the AID from CaN’s catalytic site, activating the enzyme.
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